



2023 | ANNUAL MEETING

Celebrating “U”rology: 15 years of Advancing Independent Practice

November 2 – 4, 2023

Disney’s Yacht and Beach Club Resorts
Lake Buena Vista, Florida

lugpa.org    

 **Xtandi**[®]
(enzalutamide)
40 mg tablets | 80 mg tablets

IT'S TIME FOR XTANDI

Scan the QR code to see the latest data at

XtandiHCP.com/latest



© 2023 Astellas Pharma US, Inc. and Pfizer Inc. All rights reserved. 076-8561-PM 03/23
XTANDI, Astellas, and the flying star logo are registered trademarks of Astellas Pharma Inc.



LUGPA 2023 Annual Meeting Table of Contents

| | |
|--|-----------|
| LUGPA President’s Welcome | 5 |
| Program Committee Chairman’s Welcome | 7 |
| Meeting information | 8 |
| Pre-Meeting Program Agenda | 9 |
| Practice Administrators Workshop Agenda..... | 10 |
| CME Program Agenda..... | 13 |
| Research Coordinators Working Group Agenda | 15 |
| Laboratory Directors and Managers Working Group Agenda..... | 16 |
| Annual Meeting Program Agenda..... | 18 |
| Thank You to Annual Meeting Sponsors..... | 25 |
| Thank You to Annual Meeting Exhibitors..... | 26 |
| Industry Sponsored Symposium Events | 28 |
| Exhibit Hall Floor Plan | 32 |
| Featured Speakers | 34 |
| Faculty Biographies | 36 |
| Sponsor Directory | 45 |



PLUVICTO[®]

lutetium Lu 177 vipivotide tetraxetan

INJECTION FOR INTRAVENOUS USE

Discover

what PLUVICTO has
to offer at **Booth 414**



Find a PLUVICTO
treatment center
near you

Visit us at [PLUVICTO-hcp.com](https://www.pluvicto-hcp.com) for more information





Welcome from the President



On behalf of the LUGPA Board of Directors, welcome to the LUGPA 2023 Annual Meeting. As we come together to celebrate our 15th year as the only nonprofit trade association dedicated to the advancement and preservation of the independent practice of urology it is important to note that the Annual Meeting is LUGPA's most important event with education and networking available for our constituents: urologists, advanced practice providers, administrators, managers, and healthcare industry supporters.

We are excited that this year's Annual Meeting is at a new location Disney World, to celebrate LUGPA's 15th anniversary and to offer premier educational sessions that will solve challenges and improve organizational performance. The Program Committee has organized an outstanding program for our members to experience world-class clinical education, professional and business development sessions, and updates on healthcare policy, and political affairs.

As you listen to a speaker, attend a breakout session, network during session breaks and at receptions, and talk with industry supporters in the Exhibit Hall, think about how you can develop strategies to improve operations, and empower leadership in your practice. We hope that sessions on benchmarking, organizational culture, physician and staff burnout and artificial intelligence allows you to exchange and implement new ideas that would benefit everyone; your practice, employees, and patients.

We would like to thank our industry supporters, for without their support, this meeting would not have been possible.

Thank you for attending the LUGPA 2023 Annual Meeting, your membership and for your continued support.

Sincerely,

Evan R. Goldfischer, MD, MBA, CPI
President, LUGPA

Officers

President

Evan Goldfischer, MD, MBA
Poughkeepsie, NY

President-Elect

Scott B. Sellinger, MD
Tallahassee, FL

Secretary

Jeffrey Spier, MD
El Paso, TX

Treasurer

Dave Carpenter
St. Paul, MN

Past President

Jonathan Henderson, MD
Little Rock, AR

Board of Directors

David M. Albala, MD, FACS
Syracuse, NY

E. Scot Davis, MPA, MBA, CMPE
Little Rock, AR

David J Ellis, MD, FACS
Rosemont, PA

Jason Hafron, MD
Troy, MI

Mara R. Holton, MD
Annapolis, MD

Benjamin Lowentritt, MD
Baltimore, MD

Timothy Richardson, MD
Wichita, KS

Alan D. Winkler, MHSA, FACMPE
San Antonio, TX

Chief Executive Officer

Celeste G. Kirschner, CAE


875 N. Michigan Avenue
Suite 3100
Chicago, IL 60611
www.lugpa.org



LYNPARZA is NOW APPROVED for another indication



Not an actual patient.



Visit [LYNPARZAprhcp.com](https://lynparzaprhcp.com)
to learn more



Welcome to the LUGPA 2023 Annual Meeting. We're excited to be at a new venue this year, the Disney's Yacht and Beach Club Resorts to learn, exchange ideas, and celebrate all of the accomplishments of independent urology practices. Over the course of the next three days, you will have the opportunity to experience a state-of-art conference. I am certain you will return to your practices with creative ideas and solutions to help tackle the challenges that you face each day.

This year, our meeting celebrates LUGPA's 15th anniversary and commitment to transforming and supporting the evolution of independent urology practices. This year's program will continue to showcase our political advocacy and health policy efforts as well as the business aspects of managing a urology practice.

To open our program Friday morning, best-selling author and business speaker **Ross Bernstein** will inspire and motivate you to create a culture of excellence and aim for peak performance. **Donna Shalala**, former Secretary of U.S. Health and Human Services will enlighten us on her perspectives regarding current and future healthcare regulation and policy. On Saturday, social media personality, **Dr. Will Flanary**, an ophthalmologist and comedian who moonlights in his free time as "**Dr. Glaucomflecken**," will share his experiences in the healthcare system as a physician and a two-time testicular cancer patient, as well as a survivor of cardiac arrest. We are certain he will keep you entertained.

We will honor several of our colleagues who have dedicated their time and effort to LUGPA over the last 15 years. We wish to thank Deepak Kapoor, MD, Gary Kirsh, MD and Neal Shore, MD for their service, and to Alan Winkler who will be awarded the Spirit of Independence Award and Brian C. Mazzarella, MD and Arpeet Shah, MD who have been awarded the new Trailblazer Award. We will then hear from the LUGPA Health Policy and Political Affairs leadership who will provide us with an update on regulatory and legislative policies that impact our practices, as well as recognizing our Advocate of the Year James H. Gilbaugh III, MD, FACS.

To customize your experience, this year four breakout sessions on both Friday and Saturday are offered to allow for a deeper dive on key topics.

In keeping with tradition, prior to the official start of the annual meeting, on Thursday we are conducting our half-day continuing medical education program. Additionally, there is a full-day practice administrator program, along with special programming for research coordinators, and lab directors. Finally, on Thursday we are offering a special one and half hour session conducted by the Disney Institute on the topic of employee engagement.

In the exhibit hall, our industry partners will be present to educate you on their various products and services. Please review the 2023 exhibitor list in the program book and thank all of our supporters when you meet with them during the breaks. Without their support, this meeting would not be possible.

Lastly, we have some elements of fun planned each day. On Thursday, all attendees are invited to the Networking Reception in the exhibit hall. On Friday, all attendees are invited to the Welcome Reception, where you will have another opportunity to eat, drink, and mingle with colleagues and exhibitors.

Throughout the meeting there will be industry sponsored breakfasts and lunches designed to keep you up to date on newest treatment options.

On behalf of the LUGPA Program Committee, thank you for attending the 2023 Annual Meeting. We look forward to celebrating all of our accomplishments and ways we can best position our independent group practices to meet all of challenges in the upcoming year.

Sincerely,

Jeffrey Spier, MD, FACS
Chair, LUGPA Program Committee

Program Committee

Jeffrey Spier, MD
Chair

Dave Albala, MD
Aaron Berger, MD
Fernando Bianco, MD
John Bishay, MD
Dave M. Carpenter
Ravi Chauhan, MD
Ben Coons, MD
Evan R. Goldfischer, MD, MBA
Jason M. Hafron, MD
Jonathan Henderson, MD
Vahan Kassabian, MD
Joe Kuntze, MD
Ben Lowentritt, MD
Dave Morris, MD
Andrew Pienkny, MD
Twila Puritty, MBA
Tom Rechtschaffen, MD
Hal Rosenbaum, MD
Scott Sellinger, MD
Chris Webster, MD
Alan D. Winkler, MHSA,
FACMPE

All events will take place at the Disney's Yacht and Beach Club Resorts.

Registration/Information Desk

Location: Asbury Rotunda

Wednesday, November 1, 2023

4:00pm – 7:00pm

Thursday, November 2, 2023

7:00am – 6:30pm

Friday, November 3, 2023

7:00am – 6:00pm

Saturday, November 4, 2023

7:00am – 12:45pm

Press Room

Location: Cape Cod Hall C

Thursday November 2, 2023

7:30am – 5:15pm

Friday, November 3, 2023

7:30am – 5:15pm

Saturday, November 4, 2023

7:30am – 12:30pm

CME EXHIBIT HALL

Location: Grand Harbor North Salons 1-4

Thursday, November 2, 2023

12:00pm – 5:15pm

Annual Meeting Exhibit Hall

Location: Grand Harbor Ballroom South

Thursday, November 2, 2023

5:30pm – 6:30pm

Friday, November 3, 2023

7:30am – 6:00pm

Saturday, November 4, 2023

7:45am – 10:15am

Morning Events

Thursday, November 2, 2023

7:15am – 8:15am

Practice Administrators Breakfast Buffet

Location: Newport Ballroom East

Friday, November 3, 2023

7:30am – 8:30am

Industry Sponsored Breakfast

Location: Newport Ballroom West

Sponsored by:  ImmunityBio

7:30am – 8:30am

Industry Sponsored Breakfast 2

Location: Newport Ballroom East

Sponsored by:  AstraZeneca

Saturday, November 4, 2023

7:45am – 8:45am

Industry Sponsored Breakfast

Location Newport Ballroom East

Sponsored by:  LANTHEUS

Evening Events

Thursday, November 2, 2023

5:30pm – 6:30pm

Networking Reception

Location: Grand Harbor Ballroom South

Sponsored by:  CardinalHealth

Friday, November 3, 2023

5:00pm - 6:00pm

Welcome Reception

Location: Grand Harbor Ballroom South

Conference Wi-Fi



SSID: LUGPA2023 | Password: PfizerBooth315

LUGPA 2023 Annual Meeting App

- 1. Download the Cvent Events app.** On your mobile device, download the Cvent Events app from the App Store or Google Play.
- 2. Within the app, download the event.** Once the app is open, search for the event ID **GET LUGPA2023** and tap the icon next to the event to download it. Allow notifications in order to get the latest updates and messages throughout the event.
- 3. Log in to the event.** Tap the profile button at the bottom of the screen, then log in. Enter your first name, last name, and email address used for registration.
- 4. Verify your account.** You will receive an email (check your junk mail too!) and text message containing a verification code. Return to the app and enter the verification code to complete the login process and access the event.



Wednesday November 1, 2023

**Please note that speakers and agenda topics are subject to change.*

| TIME | SESSION TITLE | LOCATION |
|-----------------|--------------------------------------|----------------|
| 4:00pm – 7:00pm | Registration/Information Desk | Asbury Rotunda |

Thursday, November 2, 2023

**Please note that speakers and agenda topics are subject to change.*

| TIME | SESSION TITLE | LOCATION |
|-------------------|---|----------------------------------|
| 7:00am – 6:30pm | Registration/Information Desk | Asbury Rotunda |
| 7:30am – 5:15pm | Press Room | Cape Cod Hall C |
| 7:15am – 8:15am | Practice Administrators Workshop Breakfast Buffet | Newport Ballroom East |
| 8:15am – 10:30am | Practice Administrators Workshop | Newport Ballroom East |
| 1:15pm – 4:30pm | Alan Winkler | |
| 10:30am – 12:00pm | Disney Institute: Employee Engagement | Grand Harbor Ballroom North |
| 12:00pm – 1:15pm | Practice Administrators Workshop Lunch | Newport Ballroom East |
| 12:00pm – 1:00pm | CME Lunch | Newport Ballroom West |
| 12:00pm – 5:15pm | CME Exhibit Hall | Grand Harbor Ballroom Salons 1–4 |
| 1:00pm – 5:30pm | CME program | Grand Harbor Ballroom North |
| 2:45pm – 3:30pm | Break in the Exhibit Hall | Grand Harbor Ballroom Salons 1–4 |
| 1:00pm – 5:15pm | Research Directors and Coordinators Working Group Twila Puritty | Asbury Hall D |
| 3:00pm – 5:15pm | Lab Directors and Managers Working Group Kirk Wojno, MD | Saybrook Room |
| 5:30pm – 6:30pm | Networking Reception | Grand Harbor Ballroom South |

Thursday, November 2, 2023

**Topics and Speakers Subject to Change*

| TIME | SESSION TITLE | LOCATION |
|-------------------|--|----------------------------------|
| 7:15am – 8:15am | Breakfast Buffet | Newport Ballroom East |
| 8:15am – 8:30am | Welcome and Introductions Alan D. Winkler, MHSA, FACMPE | Newport Ballroom East |
| 8:30am – 9:15am | Growing Revenue and Reducing Costs Kirsten Anderson Les Cavicchi Jason Guagenti Hector Santana | Newport Ballroom East |
| 9:15am – 10:00am | The Administrative Management of APPs/Ancillary Staff Angela Motler Lauren Passante Kimberly Ramsey Mike Shannon | Newport Ballroom East |
| 10:00am – 10:30am | Break and Transition Time | |
| 10:30am – 12:00pm | Disney Institute Program – Employee Engagement | Grand Harbor Ballroom North |
| 12:00pm – 1:15pm | Practice Administrators Workshop Lunch Sponsored by Verity Pharmaceuticals | Newport Ballroom East |
| 1:15pm – 2:00pm | Caring for Yourself, Your Physicians and Your Practice Dan Fellner Michelle Froehlich Allison Griffin Kim Zenkere | Newport Ballroom East |
| 2:00pm – 2:45pm | Driving Operational Efficiency Kyle Hussey Nancy Nikolovski Hector Santana Lori Tate | Newport Ballroom East |
| 2:45pm – 3:00pm | Break | Grand Harbor Ballroom Salons 1-4 |
| 3:00pm – 3:45pm | Compensation Plans Kirsten Anderson Whitt Holder | Newport Ballroom East |

Thursday, November 2, 2023

**Topics and Speakers Subject to Change*

| CONCURRENT BREAKOUT SESSIONS | | |
|------------------------------|---|-----------------------|
| 3:45pm – 4:30pm | Administrators New to LUGPA Lee Ann Shea | Asbury Hall A |
| | Planning a Strategic Retreat Dave Carpenter E. Scot Davis | Asbury Hall B |
| | Open Mic Carla Blue Stephen Gabelich Dan Schonwald | Asbury Hall C |
| | Urine PCR Reimbursement Issues Jennifer Becker | Newport Ballroom East |

THANK YOU!

NETWORKING RECEPTION

Thursday, November 2nd
 5:30pm – 6:30pm
 Grand Harbor Ballroom South



INTRODUCING THE EVOLUTION OF ELIGARD.[®]

Now in an easy to mix Pre-connected
Syringe System allowing you to
administer with more confidence.

SIMPLY
CLICK & MIX ↻



Learn more about mixing
& administering ELIGARD

Scan the QR code with your
smartphone's camera

 **Eligard[®]**
(leuprolide acetate) for injectable suspension

Thursday, November 2, 2023 | Grand Harbor Ballroom North

**Please note that speakers and agenda topics are subject to change*

| TIME | SESSION TITLE |
|------------------|---|
| 12:00pm – 1:00pm | Lunch Newport Ballroom West Sponsored by Bayer |
| 1:00pm – 1:10pm | Welcome and Introductions Gordon Brown, DO, FACOS, <i>Co-Chair, CME Program</i> Jason Hafron, MD, <i>Co-Chair, CME Program</i> |
| 1:10pm – 1:50pm | Successful Bladder Cancer Programs: What should you be offering your patients today and tomorrow? Moderator: Tom Jayram, MD Panelists: Jonathan Henderson, MD Daniel Saltzstein, MD Jay Krishnan, DO |
| 1:50pm – 2:25pm | Building a Successful Female Sexual Health Program/SPA Moderator: Guy Manetti, MD Panelists: Sarah Girardi, MD Anika Ackerman, MD |
| 2:25pm – 3:00pm | What's New in Radiation Oncology? Presenter: Dan Spratt, MD |
| 3:00pm – 3:35pm | Break in the Exhibit Hall Grand Harbor Ballroom Salons 1-4 |
| 3:35pm – 4:05pm | Good, Bad and Ugly of NEW BPH Treatments Moderator: Gregg Eure, MD Panelists: Arpeet Shah, MD Kevin Zorn, MD Tom Mueller, MD |
| 4:05pm – 4:40pm | Best Practices for Active Surveillance Moderator: Ben Lowentritt, MD Panelists: David Morris, MD Aaron Berger, MD Ronney Abaza, MD E. David Crawford, MD |
| 4:40pm – 5:25pm | The Power of Artificial Intelligence in Urology Presenters: Inderbir Gill, MD Jodi Maranchie, MD |
| 5:25pm – 5:30pm | Conclusion and Thank You Gordon Brown, DO, FACOS Jason Hafron, MD |




NUBEQA[®]
(darolutamide) 300 mg
tablets


Xofigo[®]
radium Ra 223 dichloride
INJECTION

See how **NUBEQA**[®] or **XOFIGO**[®] may
be right for your patients.

Visit nubeqahcp.com

OR SCAN
THIS QR CODE



Visit xofigohcp.com

OR SCAN
THIS QR CODE



LUGPA 2023
 Annual Meeting
**Research
 Directors and
 Coordinators
 Working Group**

Thursday, November 2
1:00pm – 5:00pm
 Asbury Hall D

**Please note that speakers and agenda topics are subject to change*

1:00pm – 2:45pm
Introductions and Regulatory Panel Presentations

Moderator:
 Twila Puritty, CEO Wichita Urology Group

Panelist:
 Amanda Ho, Regulatory Specialist, Wichita Urology Group
 Elizabeth Persels, Research Manager, Wichita Urology Group

- **Regulatory**
- Master Delegation of Authority Log
- Regulatory Policies and Procedures
- 21CFR Part 11 New Changes Compliance and Electronic Signatures
- Electronic Filing System: Do It Yourself
- **Open Discussion of Topics as Time Allows**

2:45pm – 3:30pm
Break
 Grand Harbor Ballroom Salons 1-4

3:30pm – 5:00pm
Clinical Research Panel Presentations

- **Contracting**
- Sponsor Challenges to SOC
- Liability Language
- Audits
- **Budgeting**
- Best Price list
- Sponsor Challenges to Invoiceables
- Billing and Payment Reconciliation
- Overhead Projections
- **FDA Focus**
- Diversity Of Patient Population
- Audit Prep
- **Open Discussion of Topics as Time Allows**

5:00pm
Adjourn





LUGPA 2023 Annual Meeting Lab Directors and Managers Working Group

Thursday, November 2
3:00pm – 5:15pm
Saybrook Room

Moderator:
Kirk J. Wojno, MD

**Please note that speakers and agenda topics are subject to change*

- **Histopathology/Digital Pathology**
 - o New innovations
- **Tissue workflow optimization for digital pathology**
 - o Compliance
- **NGS – Germline and Somatic**
- **Biomarkers and Guidelines**
 - o Liquid molecular
 - o Tissue molecular
 - o Chemistry
- **FDA and LDTs**
- **Molecular UTI – PCR**
- **Cytology – standardizing nomenclature**
- **FISH – reimbursement, reagents, and reflex**
- **Proficiency testing**
- **Reimbursement and political action**



For the treatment
of metastatic
castration-resistant
prostate cancer (mCRPC)¹

EXPLORE THE CAPABILITIES

OF AN INNOVATIVE ABIRATERONE ACETATE FORMULATION

YONSA[®] is the only abiraterone acetate that is FDA Approved to treat mCRPC with a 500 mg dose. It is a unique formulation with the flexibility to be taken with or without food.¹

Discover more at YONSARx.com.

Brief Summary of Prescribing Information for YONSA[®] (abiraterone acetate) tablets

This Brief Summary does not include all the information needed to use YONSA safely and effectively. See full prescribing information for YONSA.

Initial U.S. approval: 2011

INDICATIONS AND USAGE

YONSA (abiraterone acetate) is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Hypokalemia, Fluid Retention, and Cardiovascular Adverse Reactions due to Mineralocorticoid Excess: YONSA may cause hypertension, hypokalemia, and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. Monitor patients for hypertension, hypokalemia, and fluid retention at least once a month. Control hypertension and correct hypokalemia before and during treatment with YONSA.

Adrenocortical Insufficiency: Monitor for symptoms and signs of adrenocortical insufficiency, particularly if patients are withdrawn from corticosteroids, have corticosteroid dose reductions, or experience unusual stress. Symptoms and signs of adrenocortical insufficiency may be masked by adverse reactions associated with mineralocorticoid excess seen in patients treated with YONSA. If clinically indicated, perform appropriate tests to confirm the diagnosis of adrenocortical insufficiency. Increased dosage of corticosteroids may be indicated before, during and after stressful situations.

Hepatotoxicity: Can be severe and fatal. Measure serum transaminases (ALT and AST) and bilirubin levels prior to starting treatment with YONSA, every two weeks for the first three months of treatment and monthly thereafter. Re-treatment with YONSA at a reduced dose level may take place only after return of liver function tests to the patient's baseline or to AST and ALT less than or equal to 2.5X ULN and total bilirubin less than or equal to 1.5X ULN.

Increased Fractures and Mortality in Combination with Radium Ra 223 Dichloride: YONSA plus methylprednisolone in combination with radium Ra 223 dichloride is not recommended. At the primary analysis, increased incidences of fractures (22.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid.

Embryo-Fetal Toxicity: The safety and efficacy of YONSA have not been established in females. Based on animal reproductive studies and mechanism of action, abiraterone acetate can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment with YONSA and for 3 weeks after the final dose of YONSA. YONSA should not be handled by females who are or may become pregnant.

Hypoglycemia: Severe hypoglycemia has been reported when abiraterone acetate was administered to patients with pre-existing diabetes receiving medications containing thiazolidinediones (including pioglitazone) or repaglinide. Monitor blood glucose in patients with diabetes during and after discontinuation of treatment with YONSA. Assess if antidiabetic drug dosage needs to be adjusted to minimize the risk of hypoglycemia.

ADVERSE REACTIONS

The most common adverse reactions (≥ 10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and confusion.

The most common laboratory abnormalities (> 20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.

DRUG INTERACTIONS

CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during YONSA treatment. If a strong CYP3A4 inducer must be co-administered, increase the YONSA dosing frequency.

CYP2D6 Substrates: Avoid co-administration of YONSA with CYP2D6 substrates that have a narrow therapeutic index. If an alternative treatment cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate.

USE IN SPECIFIC POPULATIONS

Hepatic Impairment: Do not use YONSA in patients with baseline severe hepatic impairment (Child-Pugh Class C).

To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 FDA or 1-800-FDA-1088 or www.fda.gov/medwatch.

Manufactured for:
Sun Pharmaceutical Industries Limited.

Distributed by:
Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512

YONSA is a registered trademark of Sun Pharmaceutical Industries Limited.

All other trademarks are the property of their respective owners.

©2023 Sun Pharmaceutical Industries, Inc. All rights reserved. July 2023 PM-US-YON-0712



NEXT DESTINATION?

EXPLORING ALL THINGS GEMTESA AT BOOTH #409



◆ is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

©2023 Sumitomo Pharma America, Inc. All rights reserved. US-VBGN-2100470 (v2.0) 10/23



GEMTESA[®]

(vibegron) 75 mg tablets

Friday, November 3, 2023

*Topics and Speakers Subject to Change

| TIME | SESSION TITLE | LOCATION |
|-------------------|--|-----------------------------|
| 7:00am – 6:00pm | Registration/Information Desk | Asbury Rotunda |
| 7:30am – 5:15pm | Press Room | Cape Cod Hall C |
| 7:30am – 8:30am | Industry Sponsored Breakfast Sponsored by ImmunityBio | Newport Ballroom West |
| 7:30am – 8:30am | Industry Sponsored Breakfast Sponsored by AstraZeneca | Newport Ballroom East |
| 7:30am – 6:30pm | Exhibit Hall | Grand Harbor Ballroom South |
| 8:30am – 8:45am | Chair's Welcome and Introductions Jeffrey Spier, MD | Grand Harbor Ballroom North |
| 8:45am – 9:45am | LUGPA Presidential Update and Awards Presentation Evan Goldfischer, MD, MBA, CPI | Grand Harbor Ballroom North |
| 9:45am – 10:30am | The Champion's Code Ross Bernstein Sponsored by Verity Pharmaceuticals | Grand Harbor Ballroom North |
| 10:30am – 11:00am | Break in the Exhibit Hall | Grand Harbor Ballroom South |
| 11:00am – 11:30am | Healthcare Policy Analysis Donna E. Shalala, PhD | Grand Harbor Ballroom North |
| 11:30am – 12:45am | Q & A with Political Speaker and LUGPA's Health Policy and Political Affairs Team Donna E. Shalala, PhD Josh Langston, MD John McManus Tracy Spicer Moderators: Mara Holton, MD, and Gary M. Kirsh, MD | Grand Harbor Ballroom North |
| 11:45am – 12:30pm | Political Affair Update and Presentation of the Advocacy Award Mara Holton, MD and Josh Langston, MD | Grand Harbor Ballroom North |

Friday, November 3, 2023 continued

| TIME | SESSION TITLE | LOCATION |
|------------------|--|-----------------------------|
| 12:30pm – 1:30pm | Industry Sponsored Lunch Sponsored by: Janssen | Newport Ballroom East |
| 12:30pm – 1:30pm | Industry Sponsored Lunch Sponsored by: Myovant Sciences Pfizer Oncology | Newport Ballroom West |
| 1:30pm – 1:45pm | Break/Transition Time | |
| 1:50pm – 2:20pm | Annual LUGPA Business Meeting and Recognition of Outgoing Board Members David Albala, MD and Alan Winkler, MHSA, FACMPE | Grand Harbor Ballroom North |
| 2:20pm – 2:30pm | Break/Transition Time | |

Coming Soon!

Bladder & Kidney Cancer Academy
November 16-18, 2023
Omni Charlotte | Charlotte, NC

Presenting Partners

 **LUGPA**
Integrated Practices
Comprehensive Care

 Specialty Networks

Visit www.LUGPA.org/Events

Friday, November 3, 2023 continued

2:30pm – 3:15pm Breakout Session 1

Attendees: choose to attend one of the four Breakout Sessions

| BREAKOUT I | BREAKOUT II | BREAKOUT III | BREAKOUT IV |
|---|---|--|--|
| <p>Herding Cats: Developing a Culture of Leadership for Your LUGPA Practice Geoffrey Sklar, MD Michael Szostak, MD</p> | <p>Anatomy of a Legal Claim David Albala, MD Sean Gelsey</p> | <p>The APP’s Role in Optimizing Urologic Care: Ask the Experts Moderators: Josh Langston, MD Neal Patel, MD Panelists: Paloma Becker, NP Heather Bridgeford, MSN, RN, FNP-C Matt Gilbert, NP-C Iris Kennedy, APRN</p> | <p>LUGPA Benchmarking and Data-Deep Dive Daniel Schonwald, CMPE Cass Schaedig</p> |
| <p>Location: Grand Harbor Ballroom North</p> | <p>Location: Asbury Hall A</p> | <p>Location: Asbury Hall B</p> | <p>Location: Asbury Hall C</p> |
| <p>3:15pm – 3:50pm</p> | <p>Break in the Exhibit Hall</p> | | <p>Grand Harbor South Ballroom</p> |

4:00pm – 4:45pm Breakout Session 2

Attendees: choose to attend one of the four Breakout Sessions

| BREAKOUT I | BREAKOUT II | BREAKOUT III | BREAKOUT IV |
|---|---|---|--|
| <p>Herding Cats: Developing a Culture of Leadership for Your LUGPA Practice Geoffrey Sklar, MD Michael Szostak, MD</p> | <p>Anatomy of a Legal Claim David Albala, MD Sean Gelsey</p> | <p>The APP’s Role in Optimizing Urologic Care: Ask the Experts Moderators: Josh Langston, MD Neal Patel, MD Panelists: Chelsie Ferrell, PA Joy Maulik, CRNP Sarah Nayeboadri, PA-C</p> | <p>LUGPA Benchmarking and Data-Deep Dive Daniel Schonwald, CMPE Cass Schaedig</p> |
| <p>Location: Grand Harbor Ballroom North</p> | <p>Location: Asbury Hall A</p> | <p>Location: Asbury Hall B</p> | <p>Location: Asbury Hall C</p> |
| <p>4:00pm – 5:00pm</p> | <p>Location Asbury Hall D Empowering Women in Urology Sponsored by Boston Scientific Moderator: Kari Bailey, MD Speakers and Panelists: Katherine Amin, MD Mara Holton, MD Kristin LaRocca Jennifer Miles-Thomas, MD</p> | | <p>Grand Harbor South Ballroom</p> |
| <p>5:00pm – 6:00pm</p> | <p>Welcome Reception</p> | | <p>Grand Harbor Ballroom South</p> |

Saturday November 4, 2023

*Topics and Speakers Subject to Change

| TIME | SESSION TITLE | LOCATION |
|------------------|---|-----------------------------|
| 7:00am – 12:45pm | Registration/Information Desk | Asbury Rotunda |
| 7:00am – 12:30pm | Press Room | Cape Cod Hall C |
| 7:45am – 10:15am | Exhibit Hall | Grand Harbor Ballroom South |
| 7:45am – 8:45am | Industry Sponsored Breakfast Sponsored by Lantheus | Newport Ballroom East |
| 8:50am – 9:00am | Chair's Welcome and Friday Recap Jeffrey Spier, MD | Grand Harbor Ballroom North |
| 9:00am – 9:45am | Closing Keynote: My Perspective as a Patient and an Advocate for Patients Will Flanary, MD / AKA Dr. Glaucomflecken Sponsored by Preveta | Grand Harbor Ballroom North |
| 9:45am – 10:15am | Break in Exhibit Hall | Grand Harbor Ballroom South |

10:15am – 11:00am Breakout Session 1

Attendees: choose to attend one of the four Breakout Sessions

| BREAKOUT I | BREAKOUT II | BREAKOUT III | BREAKOUT IV |
|--|---|---|--|
| Mobilizing Your Physicians and Staff from Burnout to Professional Fulfillment Paul DeChant, MD Scott MacDiarmid, MD Jonathan Henderson, MD | LUGPA Forward Session: Using Social Media Effectively David Morris, MD Kari Bailey, MD Will Flanary, MD | Highlights of LUGPA's Executive Leadership program David Albala, MD Phil Roe, MD Erika Ferrozzo, MHA Anup Vora, MD John Tillet, MD Guy Manetti, MD Chris Mitchell, MD | Artificial Intelligence in Urology Giovanni E. Cacciamani, MD Inderbir Gill, MD Neal Patel, MD |
| Location: Asbury Hall B | Location: Asbury Hall C | Location: Asbury Hall D | Location: Grand Harbor Ballroom North |
| 11:00am – 11:15am | Transition/Break | | |

Saturday, November 4, 2023 continued

11:15am – 12:00pm Breakout Session 2

Attendees: choose to attend one of the four Breakout Sessions

| BREAKOUT I | BREAKOUT II | BREAKOUT III | BREAKOUT IV |
|--|---|---|--|
| <p>Mobilizing Your Physicians and Staff from Burnout to Professional Fulfillment Paul DeChant, MD Scott MacDiarmid, MD Jonathan Henderson, MD</p> | <p>LUGPA Forward Session: Using Social Media Effectively David Morris, MD Kari Bailey, MD Will Flanary, MD</p> | <p>Highlights of LUGPA’s Executive Leadership program David Albala, MD Phil Roe, MD Erika Ferrozzo, MHA Anup Vora, MD John Tillet, MD Guy Manetti, MD Chris Mitchell, MD</p> | <p>Artificial Intelligence in Urology Giovanni E. Cacciamani, MD Inderbir Gill, MD Neal Patel, MD</p> |
| <p>Location: Asbury Hall B</p> | <p>Location: Asbury Hall C</p> | <p>Location: Asbury Hall D</p> | <p>Location: Grand Harbor Ballroom North</p> |
| <p>12:00pm – 1:00pm</p> | <p>Industry Sponsored Lunch Sponsored by: Tolmar</p> | | <p>Newport East</p> |
| <p>1:00pm</p> | <p>Program Adjourns</p> | | |



Empowering Women in Urology



Kari Bailey, MD



Katherine
Amin, MD



Mara
Holton, MD



Kristin
LaRocca



Jennifer
Miles Thomas, MD

Friday, November 3rd

4:00pm- 5:00pm

Asbury Hall D

Session Sponsor

**Boston
Scientific**

Advancing science for life™



(kit for the preparation of gallium Ga 68 gozetotide Injection)

Experience the Illuccix Difference

Illuccix® (⁶⁸Ga-PSMA-11) has extensive clinical experience across a broad range of disease burden^{1,2}

Clinical Accuracy

Pinpoint micrometastases at the earliest signs across stages of prostate cancer in a broad range of patients.^{2,a}

High-Quality Images

Trust high-quality images across vital regions, with scan time ≤30 minutes and trained specialists ready to help.^{1,3,7-9,11}

Reliable Distribution


Order directly from over 200+ radiopharmacies nationwide, with flexible scheduling to meet the demands of your practice and on-time delivery that arrives when you need it.^{4-6,8,10}

End-to-end Support

Dedicated industry-leading support for your practice at every step, including onsite on-boarding, educational resources, and ongoing training through the Telix Network of Support.

Come Visit Our Booth!

Scan the QR Code below to learn more about Illuccix



INDICATIONS AND USAGE

ILLUCCIX, after radiolabeling with Ga 68, is for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

- With suspected metastasis who are candidates for initial definitive therapy
- With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
- For selection of patients with metastatic prostate cancer, for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk for Misinterpretation

Image interpretation errors can occur with ILLUCCIX PET. A negative image does not rule out the presence of prostate cancer, and a positive image does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget's disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.

Imaging Prior to Initial Definitive or Suspected Recurrence Therapy

The performance of ILLUCCIX for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of ILLUCCIX for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score.

Imaging to Select Patients for Lutetium Lu 177 Vipivotide Tetraxetan Therapy

The interpretation of ILLUCCIX PET may differ depending on imaging readers. ILLUCCIX PET interpretations to select patients for lutetium Lu 177 vipivotide tetraxetan therapy may be more consistent when judging gallium Ga 68 gozetotide uptake in any one tumor lesion compared to judging uptake for all lesions larger than size criteria. Multidisciplinary consultation to select patients for lutetium Lu 177 vipivotide tetraxetan therapy is recommended, particularly for ILLUCCIX imaging that a single reader finds borderline or difficult to interpret, or when patient eligibility hinges only on judgment of gallium Ga 68 gozetotide uptake for all lesions larger than size criteria.

Radiation Risks

Gallium Ga 68 gozetotide contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and healthcare providers. Advise patients to hydrate before and after administration and to void frequently after administration.

ADVERSE REACTIONS

The safety of gallium Ga 68 gozetotide was evaluated in 960 patients in the PSMA-PreRP and PSMA-BCR studies, each receiving one dose of gallium Ga 68 gozetotide. The average injected activity was 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi). The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of <1%.

In the VISION study, 1003 patients received one dose of gallium Ga 68 gozetotide intravenously with the amount of radioactivity 167.1 ± 23.1 MBq (4.52 ± 0.62 mCi). Adverse reactions occurring at ≥0.5% in patients with metastatic prostate cancer who received gallium Ga 68 gozetotide injection in the clinical study were fatigue (1.2%), nausea (0.8%), constipation (0.5%), and vomiting (0.5%).

Adverse reactions occurring at a rate of < 0.5% in the VISION study were diarrhea, dry mouth, injection site reactions, including injection site hematoma and injection site warmth and chills.

DRUG INTERACTIONS

Androgen deprivation therapy and other therapies targeting the androgen pathway

Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga 68 gozetotide PET has not been established.

Please note that this information is not comprehensive. Please see the Full Prescribing Information at illuccix.com/prescribinginformation.

You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com.

¹ As defined by the pivotal trial¹ inclusion criteria: At initial staging (N=325), all enrolled patients had an elevated PSA level ≥10ng/mL, a tumor stage of cT2b or greater, or Gleason score ≥6. BCR was defined as PSA>0.2 ng/mL more than 6 weeks after prostatectomy, or increase in serum PSA of ≥2 ng/mL above nadir after definitive radiotherapy (N=635).¹ Fendler WP, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMPI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023

² Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) prescribing information.

³ Hope TA, et al. Diagnostic accuracy of 68Ga PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multi-center prospective phase 3 imaging trial. JAMA Oncol. 2021

⁴ Massat MB. Nuclear medicine prepares for greater 68Ga demand. Appl Radiol. 2021

⁵ Data on File, Activated Sites, Telix Pharmaceuticals, 2022.

⁶ Data on File, PETNET Solutions Overview, Telix Pharmaceuticals, 2023.

⁷ Hofman MS, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study. Lancet. 2020

⁸ Velikyan I. 68Ga-based radiopharmaceuticals: production and application relationship. Molecules. 2015.

⁹ Data on File, Isotope Decay Rates, Telix Pharmaceuticals, 2022.

¹⁰ Data on File, Delivery, Telix Pharmaceuticals, 2022.

¹¹ Data on File, Customer Scan Times, Telix Pharmaceuticals, 2023

THANK YOU to our 2023 Annual Meeting Sponsors and Exhibitors

Platinum Level Partners



Gold Level Partners



Silver Level Partners



Bronze Level Partners



Exhibitors

AmerisourceBergen

Annexus Health

Artera, Inc.

BioProtect Medical, Inc.

Blue Earth Diagnostics, Inc.

Boston Scientific

Cipla USA

Cleveland Diagnostics, Inc.

Curium

Decipher Urologic Cancers

Dedicated IT

Dendreon

Endo Pharmaceuticals

Exosome Diagnostics

Fellow

Ferring Pharmaceuticals

Focal One

ForTec Medical

Foundation Medicine

GoPath Diagnostics

Invitae

Laborie Medical Technologies

mdxhealth

Medtronic

Meriplex

Modernizing Medicine

Molecular Testing Labs

Pacific Edge Diagnostics

USA Ltd.

Preveta

Prostatype Genomics Inc.

Quantib

rater8

Rivet

Siemens Healthineers

Softwave TRT

Specialty Networks

Teleflex Interventional Urology

Vision RT

Zero Prostate Cancer



THE CHAMPION'S CODE

ROSS BERNSTEIN

*Friday, November 3rd | 9:45 a.m. - 10:30 a.m.
Grand Harbor Ballroom North*

**THANK YOU
TO OUR
SPONSOR!**



Non-Muscle Invasive Bladder Cancer

QUILT-3.032 CIS with and without Papillary
QUILT-3.032 Papillary Disease Alone



Learn more at: immunitybio.com

Visit us at LUGPA, booth 304



Published November 10, 2022
NEJM Evid 2022; 2 (1)
DOI: 10.1056/EVIDoa2200167

ORIGINAL ARTICLE

IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Karim Chamie, M.D.,¹ Sam S. Chang, M.D.,² Eugene Kramolowsky, M.D.,³ Mark L. Gonzalgo, M.D.,⁴ Piyush Kumar Agarwal, M.D.,⁵ Jeffrey C. Bassett, M.D.,⁶ Marc Bjurlin, M.D.,⁷ Michael L. Cher, M.D.,^{8,9} William Clark, M.D.,¹⁰ Barrett E. Cowan, M.D.,¹¹ Richard David, M.D.,¹² Evan Goldfischer, M.D.,¹³ Khurshid Guru, M.D.,¹⁴ Mark W. Jalkut, M.D.,¹⁵ Samuel D. Kaffenberger, M.D.,¹⁶ Jodi Kaminetsky, M.D.,¹⁷ Aaron E. Katz, M.D.,¹⁸ Alec S. Koo, M.D.,¹⁹ Wade J. Sexton, M.D.,²⁰ Sergei N. Tikhonov, M.D.,²¹ Edouard J. Trabulsi, M.D.,²² Andrew F. Trainer, M.D.,²³ Patricia Spilman, M.A.,²⁴ Megan Huang, Ph.D.,²⁴ Paul Bhar, M.S.,²⁴ Sharif A. Taha, Ph.D.,²⁴ Lennie Sender, M.D.,¹⁴ Sandeep Reddy, M.D.,²⁴ and Patrick Soon-Shiong, M.D.²⁴

Summary of Efficacy in BCG-Unresponsive NMIBC CIS with or without Papillary

71%

CR Rate
At Any Time

62%

12 Months
Complete Response

53%

24 Months
Complete Response

26.6

Months Median
Duration of CR

89%

Cystectomy Free
At 24 Months

90%

Avoidance of
Cystectomy
In Responders

IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. Chamie., et al.
DOI: <https://doi.org/10.1056/EVIDoa2200167>

N-803 is an investigational product. Safety and efficacy have not been established by any health authority or agency.

All events will take place at the Disney's Yacht and Beach Club Resorts.

**Please note that speakers and agenda topics are subject to change*

Thursday, November 2

12:00pm – 1:15pm

Practice Administrators

Lunch

Location: Newport Ballroom East

Sponsored by:



12:00pm – 1:00pm

CME Lunch

Location: Newport Ballroom West

Topic:

Exploring the Role of Nubeqa (darolutamide) in mHSPC in Combination With Docetaxel and in nmCRPC

Presenter: Daniel R. Saltzstein, MD

Sponsored by:



Friday, November 3

7:30am – 8:30am

Breakfast

Location: Newport Ballroom East

Topic:

A New Combination Therapy for Certain Patients with Metastatic Prostate Cancer

Presenter: Gordon Brown, DO

Sponsored by:



7:30am – 8:30am

Breakfast

Location: Newport Ballroom West

Topic:

The Trifecta of Natural Killer Cells, Killer T Cells, and Memory T Cells in Treatment of Bladder, Renal and Prostate Cancer

Presenter: Sandeep Reddy, MD

Sponsored by:



12:30pm – 1:30pm

Lunch

Location: Newport Ballroom East

Topic:

Getting Ahead of Advanced Prostate Cancer

Presenters: David Morris, MD, FACS
 Aaron Berger, MD

Sponsored by:



12:30pm – 1:30pm

Lunch

Location: Newport Ballroom West

Topic:

A GnRH Antagonist Treatment Option for Advanced Prostate Cancer

Presenter: Bryan Mehlhaff, MD

Sponsored by:



Saturday, November 4

7:45am – 8:45am

Breakfast

Location: Newport Ballroom East

Topic:

PSMA-Targeted PET Imaging and Radioligand Therapy in the Management of Prostate Cancer: What Urologists Need to Know

Presenter: Steve Rowe, MD, PhD

Sponsored by:



12:00pm – 1:00pm

Lunch

Location: Newport Ballroom East

Topic:

Evidence-Based, Practical Strategies for Providing Comprehensive Care to Men on Androgen Deprivation Therapy

Presenter: E. David Crawford, MD

Sponsored by:





With more than 65 years of
experience in delivering
life-changing science,
Lantheus is committed to
improving patient outcomes
through diagnostics,
radiotherapeutics and
artificial intelligence solutions
that enable clinicians to
Find, Fight and Follow[®]
disease to deliver better
patient outcomes.



LANTHEUS™

Learn more about what we do:
Lantheus.com

Connect with us on social media:

 @Lantheus

 @LantheusNews

Congratulations to Award Recipients

Presidential Citation Award

Presidential Citation Award is presented to an individual for outstanding contributions to LUGPA that were critical to LUGPA's mission, including political affairs, health policy, and education.



Deepak A. Kapoor, MD

Dr. Kapoor is Chairman and Chief Ecosystem Officer of Solaris Health Holdings, LLC, Market President for Integrated Medical Professionals, PLLC (IMP) and President of Advanced Urology Centers of New York. His expertise includes basic science research in molecular biology, as well as extensive experience in oncologic and reconstructive surgery.

Dr. Kapoor is Clinical Professor of Urology at the Icahn School of Medicine at Mount Sinai, Chair of the LUGPA Health Policy Committee, Past President of LUGPA, and Chairman of SCRUBS RRG. He has also served as a Director of UroPAC and Chairman of Access to Integrated Cancer Care. Dr. Kapoor was founder of the New York Urology Trade Association and Integrated Medical Foundation. In addition, he is a Fellow of the American College of Physician Executives.

Dr. Kapoor has published and lectured extensively on clinical, business and health policy issues and is Associate Editor of the journal *Urology Practice*. He serves on a number of medical advisory boards, including the New York State Governor's Prostate Cancer Advisory Panel. Dr. Kapoor has received numerous accolades, including the 2011 AUA Ambrose-Reed socioeconomic essay award, the 2014 New York Section AUA Russell W. Lavengood distinguished service award and was recognized in 2018 by LUGPA for outstanding contributions to health policy and the preservation of independent medicine.



Gary M. Kirsh, MD

Dr. Kirsh is the President of The Urology Group, a 35-urologist integrated group practice headquartered in Cincinnati, Ohio. He has served as the group's President since 2009. In 2008, Dr. Kirsh was instrumental in founding LUGPA. He has served as Secretary, President-Elect, and President (2014-2016) of LUGPA. Currently, Dr. Kirsh is the Chair of the LUGPA Political Affairs Committee.

Dr. Kirsh has frequently spoken to urologists across the country on the socioeconomic and political issues facing urology and organized medicine. He has maintained longstanding relationships with various legislators and their staff, and has provided legislative testimony in support of physicians' issues at both the state and Congressional levels.

Clinically, Dr. Kirsh has special interest in prostate cancer and, more recently, in advanced prostate cancer. He is the director of the Advanced Prostate Cancer Clinic at The Urology Group and lectures often on this topic.

Dr. Kirsh earned his medical degree from the University of Chicago, Pritzker School of Medicine in 1984. He completed his urology residency at Case Western Reserve University in Cleveland, Ohio, in 1989. Dr. Kirsh resides in Cincinnati, Ohio with his wife Nora. Their two children reside in Boston and Washington, DC



Neal Shore, MD, FACS

Dr. Neal Shore graduated both Duke University and Duke University Medical School. He completed his general surgery/urology residence at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He is the Medical Director, for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr Shore has conducted more than 400 clinical trials, focusing mainly for GU Oncology indications. He is the Chief Medical Officer, Surgery/Urology, for GenesisCare, US. He has more than 250 peer reviewed publications and numerous book chapters. He serves on the SITC Guidelines Committee for Bladder Cancer as well as the boards of the Bladder Cancer Advocacy Network and the Duke Global Health Institute. He is the former Chair of the LUGPA Education Committee and past LUGPA Board President. He is on the editorial boards of *Reviews in Urology*, *Urology Times*, *Chemotherapy Advisor*, *OncoLive*, *PLOS ONE*, *Urology Practice*, *World Journal of Urology*, and also serves as Editor, *Everyday Urology-Oncology*. He is a Fellow of the American College of Surgeons.

Spirit of Independence Award

Spirit of Independence Award is presented to an individual for exemplary initiatives, service, and outstanding accomplishments in independent urology and LUGPA.



Alan D. Winkler, MHA, FACMPE

With forty years of experience in healthcare, Alan D. Winkler has served as the Executive Director of Urology San Antonio, P.A. since October 2012. Alan holds a Master's degree in Health Services from the University of Arkansas for Medical Sciences and has worked in private and corporate settings with physicians of many specialties. Alan is a Fellow in the American College of Medical Practice Executives and served on its board of directors for nine years, concluding as its chair. Alan currently serves on the LUGPA Board of Directors and chair of the Practice Administrators Committee.

Trailblazer Award

The Trailblazer Award is a prestigious recognition bestowed upon urologists or administrators who have significantly contributed to the field within the first ten years of their practice.



Brian C. Mazzarella, MD

Dr. Brian Mazzarella grew up in Austin and completed his undergraduate degree at The University of Texas. While completing his degree, Dr. "Mazz", as he is often called, worked part-time as a volunteer firefighter and EMT. He then attended The University of Texas Health Science Center at San

Antonio. He completed his surgery internship at Parkland Hospital in Dallas and his urology training at the renowned University of Texas Southwestern Medical Center.

Dr. Mazzarella practices general urology at Urology Austin. He has overseen and built the Urology Austin clinical trial team from ground up. In this capacity, he has become a highly experienced investigator and has run studies in many subspecialties in urology. He is a Certified Principal Investigator by the ACRP. He serves as an Affiliate Faculty Member for the Dell Medical School. Dr. Mazz has traveled extensively, both nationally and internationally, to teach surgical techniques to his colleagues.

Dr. Mazzarella also serves as the Vice President of Research for Urology America where he is charged with replicating and scaling the successes of the Urology Austin research team at all Urology America locations.



Arpeet Shah, MD

Dr. Shah brings a wealth of leading-edge knowledge and experience to his compassionate care. He is a fellowship trained, board-certified urologist with a particular interest in robotic and minimally invasive urological surgery. He performs complex robotic procedures including prostatectomy, cystectomy, nephrectomy, partial nephrectomy, nephroureterectomy, pyeloplasty, and ureteral reimplantation. He also has an interest in minimally invasive BPH procedures including Rezum, UroLift, Greenlight PVP, Aquablation and robotic simple prostatectomy.

Alongside his clinical role, Dr. Shah is on the AUS leadership team and serves as the Director of APP Program. Dr. Shah also serves as a member of the National Clinical Board of Solaris, a national urology platform. He also is on the Robotic Surgical Committee at Advocate South Suburban Hospital and the Surgical Quality Committee at University of Chicago Ingalls Memorial Hospital.

His collegiate education began as part of the prestigious Guaranteed Professional Program Admissions (GPPA) Medical

Scholars Program at University of Illinois at Chicago where he completed his Bachelor in Sciences in Biology *summa cum laude*. He then completed his Doctorate in Medicine at University of Illinois at Chicago with a distinctive honor of being a member of the Urban Medicine Program. He then went on to Loyola University Medical Center and completed his internship in general surgery, residency in urology, and fellowship in robotic surgery and endourology. A true asset to his field, he is board-certified in urology by the American Board of Urology (ABU).

Licensed to practice medicine in Illinois and Indiana, Dr. Shah holds privileges at Advocate South Suburban Hospital, UChicago Medicine Ingalls Memorial, and Community Hospital- Munster. He is a member of several professional associations, including the American Urological Association, Chicago Urological Society, and the North Central Section of the American Urological Association.

Throughout his fruitful career, Dr. Shah has published over 30 peer reviewed articles that have contributed to the subject of urology and like topics. When he's not in the office, Dr. Shah enjoys playing golf, listening to music as well as playing the drums and piano. He also likes to travel and ride bikes.


Advocate of the Year

The Advocate of the Year is presented to an individual for their work in healthcare advocating for urology and independent practice.



Dr. James H. Gilbaugh III, MD, FACS

A practicing urologist at Wichita Urology, Group Dr. Gilbaugh received his medical degree from Oregon Health Sciences University, Portland, OR. He completed his internship and residencies in the specialties of surgery and urology at UCSD Medical Center, San Diego, CA. Dr. Gilbaugh also did a fellowship in Male Reproductive Medicine and Surgery at Baylor College of Medicine, Scott Department of Urology in Houston, TX. Board certified by the American Board of Urology; Dr. Gilbaugh has been in practice since 1994.



| Industry Partners | Table # |
|-------------------------------------|---------|
| AbbVie | 210 |
| Accord BioPharma | 314 |
| AmerisourceBergen | 404 |
| Annexus Health | 203 |
| Artera, Inc. | 110 |
| Astellas Pharma and Pfizer Oncology | 307 |
| AstraZeneca | 201 |
| Bayer | 402 |
| BioProtect Medical, Inc. | 107 |
| Blue Earth Diagnostics, Inc. | 309 |
| Boston Scientific | 316 |
| CG Oncology, Inc | 108 |
| Cipla USA | 113 |
| Cleveland Diagnostics, Inc. | 413 |
| Curium | 509 |
| Decipher Urologic Cancers | 215 |
| Dedicated IT | 310 |
| Dendreon Pharmaceuticals, LLC | 407 |
| Endo Pharmaceuticals | 308 |
| Exosome Diagnostics | 115 |
| Fellow | 216 |
| Ferring Pharmaceuticals | 214 |
| Focal One | 109 |
| ForTec Medical | 111 |
| Foundation Medicine | 207 |
| GoPath Diagnostics | 408 |
| ImmunityBio | 304 |
| Invitae | 416 |
| Janssen Biotech, Inc. | 302 |

| Industry Partners | Table # |
|-----------------------------------|-----------|
| Laborie Medical Technologies | 213 |
| Lantheus | 501 |
| mdxhealth | 401 |
| Medtronic | 208 |
| Merck & Co., Inc. | 303 |
| Meriplex | 515 |
| Modernizing Medicine | 209 |
| Molecular Testing Labs | 510 |
| Myriad Genetics, Inc. | 202 204 |
| Novartis | 414 |
| Pacific Edge Diagnostics USA Ltd. | 503 |
| Pfizer | 315 |
| Preveta | 101 |
| Prostatype Genomics Inc. | 513 |
| Quantib | 313 |
| rater8 | 104 |
| Rivet | 410 |
| Siemens Healthineers | 116 |
| Softwave TRT | 105 |
| Specialty Networks | 516 |
| Sumitomo Pharma America, Inc. | 102 409 |
| Sun Pharmaceuticals, Inc. | 415 |
| Teleflex Interventional Urology | 114 |
| Telix Pharmaceuticals | 301 |
| Tolmar Pharmaceuticals, Inc. | 504 |
| UroGen Pharma, Inc. | 403 |
| Vision RT | 507 |
| Zero Prostate Cancer | 103 |

PREVETA 

A Care Navigation platform

Improving outcomes
with data-driven care
pathways

Visit us
at booth **#101**

to learn how Preveda can supercharge
your care navigation team and enter
our grand prize raffle!

[Preveda.com](https://www.preveda.com)



Ross Bernstein
Friday November 3, 2023

“Champion’s Code”

A best-selling author, Ross Bernstein is also a peak-performance business speaker who examines what makes champions in sports and relates those qualities to business successes.

Mr. Bernstein inspires his audience with the “Good to Great” concept of how the best companies are able to separate themselves from the rest of the pack through dynamic leadership, by creating a culture of excellence, by developing deeper relationships, and by giving extraordinary customer experiences.



Donna E. Shalala, PhD
Friday November 3, 2023

A distinguished educator, Dr. Shalala is Trustee Professor of Political Science and Health Policy at the University of Miami. She was President of the University of Miami (2001-2015), Chancellor of the University of Wisconsin-Madison (1987-1993), and President of Hunter College of the City University of New York (1980-1987).

One of the most honored academics of her generation, she has been elected to seven national academies including the National Academy of Medicine, the National Academy of Education, the American Academy of Arts and Sciences, and the American Philosophical Society. She has more than five dozen honorary degrees from American and International Universities. She is also a member of the Council on Foreign Relations. One of the country’s first Peace Corps Volunteers (Iran), her public service also includes serving as Secretary of the US Department of Health and Human Services in the Clinton administration for eight years. In 2008 President George W. Bush selected her as the recipient of the Presidential Medal of Freedom, the nation’s highest civilian award. She was named one of “America’s Best Leaders” by U.S. News & World Report (2005), received the Nelson Mandela Award for Health and Human Rights (2010), and was inducted into the National Women’s Hall of Fame (2011).

Professor Shalala received her B.A. from Western College for Women and her PhD from Syracuse University.



Will Flanary, MD
Friday November 3, 2023

“Perspectives as a Patient and Becoming an Advocate for Patients”

Will Flanary is an ophthalmologist and comedian who moonlights in his free time as “Dr. Glaucomfleckchen,” a social media personality who creates medical-themed comedy shorts to an audience of over 3 million across social media. His humor has been shaped by his experiences in the healthcare system as a physician and patient. Will is a 2-time testicular cancer survivor as well as a survivor of cardiac arrest, saved by his intrepid wife and her timely CPR. Initially used as a creative outlet to cope with these health challenges, Will’s comedy has evolved over time to incorporate biting satire of the US healthcare system, academic publishing, and interpersonal conflicts pervasive in the medical system. He is a frequent keynote speaker who encourages medical audiences to embrace humor in every day life.



Artist rendering; for illustration purposes only.

In RCC, all T3 tumors are characterized by their invasiveness.¹

These tumors extend into structures within or adjacent to the kidney system, including the renal fat, the renal vein, the vena cava, or the pelvicalyceal system.^{1,a}

Patients with more invasive tumors are at a higher risk of their cancer returning.²

Identify patients in your practice who have T3 tumors so you can take appropriate action following nephrectomy.

How will you manage your next patient with an invasive T3 tumor?

^aT3 tumors do not extend beyond Gerota's fascia or into the ipsilateral adrenal gland.¹
RCC = renal cell carcinoma.

References: 1. Edge SB, Greene FL, Byrd DR, et al, eds. Kidney. In: *AJCC Cancer Staging Manual*. 8th ed. Springer International Publishing; 2017:739–748. 2. Sundaram M, Song Y, Rogerio JW, et al. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: a retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data. *J Manag Care Spec Pharm*. 2022;28(10):1149–1160. doi:10.18553/jmcp.2022.22133.



David M. Albala, MD

Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr. Albala was an endourology fellow at Washington University Medical Center under the direction of Ralph V. Clayman. He practiced at Loyola University Medical Center in Chicago and rose from the ranks of Instructor to full Professor in Urology and Radiology in eight years. Ten years later, he became a tenured Professor at Duke University Medical Center in North Carolina. At Duke, he was Co-Director of the Endourology fellowship and Director for the Center of Minimally Invasive and Robotic Urological Surgery. He has over 247 publications in peer-reviewed journals and has authored three textbooks in endourology and seven in general urology. He is the Editor-in-Chief of the Journal of Robotic Surgery. He serves on the editorial board for Medical Reviews in Urology, Current Opinions in Urology and Urology Index and Reviews. He serves as a reviewer for eight surgical journals. He is a Visiting Professor in the Department of Urology at SUNY Downstate Health Sciences University. In addition, he was ranked among the top 2% of urologists in the world by a Stanford University study done in May 2021.

At the present time he is Chief of Urology at Crouse Hospital and a member of Associated Medical Professionals in Syracuse, New York. He is considered a national and international authority in laparoscopic and robotic urological surgery and has been an active teacher in this area for over 20 years. His research and clinical interests have focused on robotic urological surgery. In addition, other clinical interests include minimally invasive treatment of benign prostatic hypertrophy (BPH), biomarkers in prostate cancer, and the use of fibrin sealants in surgery. He has been a Visiting Professor at numerous institutions across the United States as well as overseas in countries such as India, China, Iceland, Germany, France, Japan, Brazil, Australia, and Singapore. In addition, he has done operative demonstrations in over 32 countries and

23 states. He has trained 19 fellows in endourology and advanced robotic surgery.

In addition, Dr. Albala is a past White House Fellow who acted as a special assistant to Federico Pena, Secretary of Transportation, on classified and unclassified public health related issues.



Dr. Katherine Amin, MD

Dr. Katherine Amin, MD, has joined the University of Miami Health System as assistant professor of clinical urology.

Clinical Specialties:

Female pelvic floor reconstruction, pelvic organ prolapse, urinary incontinence, minimally invasive surgery/robotic surgery, neurourology, fecal incontinence, transvaginal mesh complications, obstetric fistula, female sexual health, lower urinary tract disease, male voiding dysfunction

Research Interests:

Outcomes of frail older adults undergoing urologic procedures, pelvic organ prolapse outcomes, preventative health initiatives for women.

Education Fellowship – Female Pelvic Medicine and Reconstructive Surgery, Virginia Mason Medical Center, 2019
Residency – Urology, Mount Sinai Medical Center (New York), 2017
M.D. – University of Buffalo, 2012



Kari Bailey, MD

Dr. Kari Bailey has spent most of her life in Maryland. She completed her Urology training in Massachusetts and came back to Maryland to start her career and raise her family.

Dr. Bailey earned her undergraduate degree and medical school degree at the University of Maryland. She completed her general

surgery internship and urologic residency at Lahey Hospital and Medical Center in Burlington, Massachusetts.

Dr. Bailey treats a broad range of general urologic conditions in both men and women. She has a special interest in female urology including incontinence, overactive bladder, and sexual health.



Paloma Becker ACNP

Ms. Paloma Becker is an acute care nurse practitioner. She received her Master's degree from the University of Texas at El Paso. She has worked with Rio Grande Urology in El Paso Texas for the past 6 years and is a member of the American Urological Association. Ms. Becker serves the inpatient and outpatient urology populations. She treats a wide variety of general urologic conditions some of which include, but are not limited to: kidney stones, bladder cancer, prostate cancer, overactive bladder, as well as caring for acutely ill patients in the hospital during call coverage.



Heather N. Bridgeford, RN, MSN FNP-C

Ms. Bridgeford has provided urology care at Urology San Antonio for nine years with a focus in women's urology including treatment for overactive bladder, urinary incontinence, urinary tract infections, pelvic floor prolapse using urodynamics. She completed her bachelor's and graduate degrees in nursing at the University of Texas Health Science Center at San Antonio. Ms. Bridgeford is certified as a family nurse practitioner.



Giovanni E. Cacciamani, MD

Dr. Giovanni E. Cacciamani is an Italian urological surgeon and physician-scientist. He is an Associate Professor of Urology and Radiology at the Department of Urology of the University of Southern California and Co-Director of the Artificial Intelligence Center for Surgical and Clinical Application in Urology and Vice-chair of the Research Council at the Department of Urology of USC. Cacciamani earned his Medical Degree (M.D.) and Master of Science (M.Sc.) in Medicine and Surgery in 2013 from the University of Verona. He completed a Urology residency in 2018 at “Confortini” Hospital, the University of Verona. In 2018 he completed a Minimally Invasive Surgery Research fellowship at the University of Southern California.

Dr. Cacciamani’s primary areas of interest are Urological Oncological diseases (Prostate Cancer, Renal Cancer, and Bladder Cancer), Patients safety, and Artificial Intelligence applications in healthcare, with a particular interest in the use of machine learning for the identification of radiomics features to predict the pathology from the imaging and in the detection of predictors of recurrence of urological malignancies.

Dr. Cacciamani has published 230 publications in international peer-review journals of reference in the Urologic-oncological scientific field, 8 Prospero Protocols (University of York), 15 book chapters, and the author of more than 150 abstracts in national and international meetings. In 2021 Dr. Cacciamani received the “Matula Award 2021” for the best Italian urologist under 40 and was awarded the “Citizen of the Year 2021” in Verona for the category “healthcare.” Dr. Cacciamani is a member of eleven professional societies in the urological field. He is the Chairman of the Young Academic Urology (YAU) Working party of the European Association of Urology in Uro-Technology (2021-present) and a Board member of the European Association of Urology Research Foundation. In July 2020, he obtained the 10-years National Scientific Qualification for Associate Professorship (clinical and research) in Urology by the Italian Ministry of University and Research.



Dr. Paul F. DeChant, MD, MBA, FAAFP

Principal and Co-Founder, Organizational Wellbeing Solutions, LLC

Dr. Paul DeChant advises C-level healthcare executives on managing critical problems such as financial and staffing challenges by addressing the root causes of clinician burnout.

Following 25 years practicing family medicine in settings as varied as the San Francisco bay area, Breckenridge Colorado, and Geisinger Health in Central Pennsylvania, he became CEO of the Sutter Gould Medical Foundation, where he led a transformation that achieved recognition for the group as the highest performing among 170 medical groups across the State of California two years in a row, while improving physician satisfaction from the 45th to 87th percentile on AMGA’s Provider Satisfaction Survey.

He received his MD from the Oregon Health Sciences University and his MBA from the University of Colorado-Denver. Co-author of the book, “Preventing Physician Burnout: Curing the Chaos and Returning Joy to the Practice of Medicine”, Paul speaks internationally, and blogs regularly at www.pauldechantmd.com



Chelsie Ferrell, PA

Mrs. Ferrell received her Bachelor of Science Degree in Biology from the University of Missouri in 2009. She received her Masters of Science degree in Medical Science from Nova Southeastern University in 2013, where she was a Chancellors List Scholar.

She began her career at Advanced Urology Institute of Florida in 2013 where she continues to practice in general urology with a special emphasis on advanced prostate cancer. She is the chair of AUI’s APP Committee and has experience as a national speaker/educator.



**Erika Ferrozzi, MHA
 Chief Operating Officer**

Erika Ferrozzi joined Idaho Urologic Institute and Surgery Center of Idaho in May of 2021. In her time at IUI/SCI, Erika has worked with the team to recoup nearly \$3M in revenue recovery, improved care line processes, and has implemented lean process improvements that have resulted in significantly improved patient and provider satisfaction. Erika has more than 15 years of administrative leadership experience encompassing 13 specialties, and a combined impact reaching more than 500 staff and providers. Erika has proven to be a results-focused and highly engaged leader skilled at leading change initiatives with a verifiable record in delivering measurable improvements in operational and clinical performance. Erika has an exceptional ability to implement change management strategies, achieving operational objectives and establishing effective teams. Erika has a proven track record leading primary care, surgical specialties, ambulatory surgery centers, and specialty divisions with exceptional provider workplace satisfaction, patient satisfaction, and employee engagement.

Erika earned a Master’s in Public Health, Healthcare Administration from National University and received the Presidents Chair Award for Academic Excellence, a Bachelor of Science in Kinesiology with an emphasis in Sports Medicine from San Diego State University and is a member of the Gamma Phi Beta honors society for academic excellence, service, and character. In addition, Erika is a certified Lean Six Sigma Black Belt, a certified HBI Revenue Cycle Leader, a certified HBI Patient Access Specialist, is in process of completing the Project Management Professional Certification, is in the process of sitting for the CMPE exams and is in the process of satisfying the American College of Healthcare Executives requirements to become a fellow.



Sean Gelsey

Mr. Gelsey has more than 20 years experience in claims management on a national and international level for both government and insurance industries. Prior to working for COPIC, Mr. Gelsey retired from the United States Air Force and worked in insurance as a Senior Claims Professional, specializing in complex medical and general liability claims across multiple states. He represents COPIC at numerous conferences, and by sitting on boards and serving through committee memberships. Mr. Gelsey holds a Masters in Business Administration from the University of Colorado Boulder and continues to mentor others in insurance, leadership, and finance.



Matt Gilbert, NP

Mr. Gilbert has been with Urology of Virginia specializing in men's health for over three years. He is a member of the Androgen Society and the American Urological Association, and has advanced training in Testosterone therapy, Erectile Dysfunction, Male Infertility, Benign Prostatic Hyperplasia and male voiding dysfunction, and kidney stone disease. Prior to joining Urology of Virginia Matt worked in the Sentara system for many years.



Inderbir S. Gill, MD

Inderbir S. Gill, MD, is distinguished professor and chairman, Catherine & Joseph Aresty Department of Urology; executive director, USC Institute of Urology; and the

Shirley & Donald Skinner Chair in Urologic Cancer Surgery at the Keck School of Medicine, University of Southern California, Los Angeles. Prior to this, he was chairman & professor, department of urology at the Cleveland Clinic, Cleveland, OH, where he was on faculty for 12 years (1997-2009).

During his 13 years in Los Angeles since 2009, USC Urology has grown in scientific stature, clinical volumes, financial productivity & philanthropy. As a result, USC Urology has progressed in *U.S. News & World Report* national rankings from being outside the 'Top 50' until 2011, to #4 in 2019, and has ranked in the 'Top 10' for 5 years in a row (2018-2022). In NIH Blue Ridge national rankings, USC Urology elevated from #26 in 2017 to #2 nationally (2022, 2023).

Dr Gill has published ~870 scientific papers with ~41 000 citations. His H-index is 112, amongst the highest in the field of urology. He is principal investigator of a funded R-01 grant from NCI, and co-PI on other NIH grants. He is published in prestigious journals including *N. Engl. J. Med.*, *Nature Medicine*, *Lancet*, *Lancet Oncology*, *JAMA Surgery*, etc. He has edited/co-edited 10 textbooks and has been on the editorial boards of 9 urologic journals. He has been invited for over 450 visiting professorships, invited lectures and live surgery demonstrations world-wide. He is elected to the prestigious American Association of Genito-Urinary Surgeons (2003) and the Clinical Society of AAGUS (2009).

His various honors include: the Dr. B. C. Roy National Award for Eminent Medical Person awarded by the President of India (2005); St. Paul's Medal by the British Urological Association (2006); honorary Fellow of the Royal College of Surgeons of England; President, 24th World Congress of Endourology & SWL (2006); USC Presidential Medallion (2013); listed in Thomson Reuters "The World's Most Influential Scientific Minds" (2014); AUA Ramon Guiteras Lecturer (2015); AUA Chair, Global Initiatives (2015-2017); AAGUS Membership Committee (2021-2025); AUA Presidential Citation for Outstanding Contributions to Robotic Urologic Oncologic Surgery (2022); and SIU Distinguished Career Award by the Societe' Internationale D' Urologie (2022).

His primary academic focus is advanced robotic urologic oncologic surgery for cancers of the kidney, bladder and prostate. His aggregate team has amongst the world's pre-eminent robotic/laparoscopic case volumes for urologic oncologic surgery, with over 15,000 cases in the USA. More recently,

his interest has expanded to focal targeted therapy for prostate cancer. He and his team are now exploring artificial intelligence (AI) applications in urology. In 2021, under his leadership, USC Urology established the nation's first, foundation-funded, dedicated Urology AI Center in a urology department.

Dr Gill has had the enormous privilege to train numerous urology residents and over 120 minimally invasive urologic oncology fellows. His fellows and faculty members are also making innovative contributions to the field. Notably, at this writing, 12 of them are current Chairs of highly prestigious urology departments nationally and internationally.



Evan R. Goldfischer, MD, MBA, CPI, LUGPA President

Dr. Goldfischer received his BA from Tufts University and his MD from Cornell University Medical College. He completed his internship in general surgery and his residency in urology at the University of Chicago. He completed a fellowship in endourology under the direction of Arthur Smith at Long Island Jewish Medical Center. Dr. Goldfischer received his MBA from the University of Massachusetts and is a Certified Physician Executive. He served as the co-founding CEO of Premier Medical Group of the Hudson Valley, as well as founding Director of Research.

Dr. Goldfischer has written over 100 peer-reviewed abstracts and publications and has lectured on six continents. In addition, he was elected to the LUGPA Board of Directors in 2014 currently serving as President. He is the Editor-in-Chief of Practice Management for Urology Groups: LUGPA's Guidebook Second Edition published in 2020 and is the author of *Even Urologists Get Kidney Stones – A Guide to Prevention and Treatment*, published in 2018.



Jonathan Henderson, MD

Dr. Henderson earned a Bachelor of Science Degree at LSU in Baton Rouge in microbiology. After receiving his M.D. at LSU Medical Center in Shreveport, he completed his internship and residency in Urology at LSUMC Hospital.

Dr. Henderson spent the next six years in practice in Alabama where he pioneered urologic laparoscopy. In 2002, Dr. Henderson was asked to return to Shreveport to join the nascent Regional Urology and served as CEO. In March 2022 Dr. Henderson joined Arkansas Urology in Little Rock, Arkansas.

Dr. Henderson is certified by the American Board of Urology. He is a member of the American Urologic Association (and sits on many committees for that organization), Shreveport Medical Society, Louisiana State Medical Society, and the Alpha Omega Alpha Medical Honor Society. He has been on the LUGPA Board of Directors since 2011 and is the Immediate Past President.



Amanda Ho

Amanda Ho is currently employed as the Clinical Research Regulatory Specialist at Wichita Urology Group in Wichita, Kansas. Amanda has over twenty-one years of experience in healthcare with twelve of that being in clinical research as a lead regulatory specialist. Amanda's prior experience includes serving as a Clinical Research Regulatory Specialist in groups specializing in cardiology and medical oncology. Amanda's experience is currently being shared with a local nephrology practice.

In her two years with Wichita Urology Group, Amanda has successfully transformed clinical research's regulatory time management by revamping policies and procedures, creating new delegation of authority logs, converting

a paper filing system to electronic files, and built a patient database from scratch.

Amanda's professional passions include teaching others, overcoming challenges, difficult conversations, and exchanging ideas with the top performers in research. She is overjoyed when teaching others time management ideas and her tips of the regulatory trade.

Amanda's enthusiasm to help others succeed is evidenced by her ability to meet others where they are in their regulatory journey. Over her career, she has provided one-on-one consultations with other regulatory specialists in diverse medical specialties. Amanda absolutely enjoys sharing her experience and knowledge with others.



Mara R. Holton, MD

Founder and Director, Women's Wellness Center at Anne Arundel Urology

Dr. Mara Holton graduated from Temple University School of Medicine in 2001. She received her surgical and urology training at the University of Maryland Medical Center. She is certified by the American Board of Urology and is licensed in the state of Maryland. She is clinically focused on the care of women's urological and pelvic floor health and has served as the CEO of her group, Anne Arundel Urology, for the past 4 years. She is a Board member of LUGPA, a member of the American Urological Association and is the founder and director of the Women's Wellness Center at Anne Arundel Urology.



Iris Kennedy, APRN

Iris Kennedy joined Arkansas Urology in 2008. Kennedy started her medical training at the Julio Trigo Medical School in Havana, Cuba in 1989. She graduated from the

University of Arkansas for Medical Science in 2005. Iris is the Clinical Director of Urology Cancer Services at Arkansas Urology. She is a member of Sigma Theta Tau Honor Society. Her prior experience includes emergency medicine, general and vascular surgery and gastroenterology.



Gary M. Kirsh, MD

Dr. Kirsh is the President of The Urology Group, a 35-urologist integrated group practice headquartered in Cincinnati, Ohio. He has served as the group's President since 2009. In 2008, Dr. Kirsh was instrumental in founding LUGPA. He has served as Secretary, President-Elect, and President (2014-2016) of LUGPA. Currently, Dr. Kirsh is the Chair of the LUGPA Political Affairs Committee.

Dr. Kirsh has frequently spoken to urologists across the country on the socioeconomic and political issues facing urology and organized medicine. He has maintained longstanding relationships with various legislators and their staff, and has provided legislative testimony in support of physicians' issues at both the state and Congressional levels.

Clinically, Dr. Kirsh has special interest in prostate cancer and, more recently, in advanced prostate cancer. He is the director of the Advanced Prostate Cancer Clinic at The Urology Group and lectures often on this topic. Dr. Kirsh earned his medical degree from the University of Chicago, Pritzker School of Medicine in 1984. He completed his urology residency at Case Western Reserve University in Cleveland, Ohio, in 1989. Dr. Kirsh resides in Cincinnati, Ohio with his wife Nora. Their two children reside in Boston and Washington, DC.



Joshua Langston, MD

Dr. Joshua Langston is a urologist and the Chief Medical Officer at Urology of Virginia, a 50 provider group based in Virginia Beach, VA. After residency training at the University of North Carolina – Chapel Hill, he completed a fellowship in Andrology & Male Reconstructive Urology at the Institute of Urology in London, England. His clinical practice focuses on men's health and cancer survivorship, and he founded and directs Men's Health Virginia, a division of Urology of Virginia.

In addition to clinical pursuits, Dr. Langston has a strong interest in health policy, advocacy and physician leadership in medicine. He was selected as the American Urological Association's 2017 Holtgrewe Legislative Fellow, spending time as a health policy legislative advisor in the U.S. Senate. He is a member of the Political Affairs Committee for the Large Urology Group Practice Association where he was awarded their 2019 Advocate of the Year award. He is Co-Chair of the Regulatory Affairs Committee and a member of the Political Affairs and Practice Management Committees for the American Urological Association. While in the U.K., Dr. Langston was selected to participate in the Executive Mentoring Program sponsored by NHS England for doctors with special interest in executive leadership in medicine. He serves on the Board of Directors for the American Society for Men's Health, as well as a number of other boards and advisory groups.



Kristin LaRocca

Senior Vice President
Head of Sales & Channel Innovation
Urology and Pelvic Health

Kristin LaRocca joined Boston Scientific in 1994. LaRocca started her career at BSC working as a Territory Sales Manager,

working her way up to Director of Sales Operations and Training. In 2010, LaRocca transitioned roles and became a Sales Director and is now Sr. Vice President, Head of Sales & Channel Innovation. As head of field sales UroPH, LaRocca's responsibilities include MedSurg National Accounts & Emerging Channel Strategy, Sales Enablement, Commercial Operations, Capital Equipment Service and Sales Training and Organizational Development.



Scott A. MacDiarmid, MD

Dr Scott MacDiarmid is director of the Alliance Urology Specialists Bladder Control Center in Greensboro, NC. He completed fellowships in reconstructive urology and urodynamics at Duke University Medical Center in Durham, NC; the University of Otago in Christchurch, New Zealand; and the University of Sheffield in England. He is currently a clinical professor of Urology in the Department of Urology, at the University of North Carolina, in Chapel Hill, NC.

Dr MacDiarmid's clinical, educational, and academic expertise is in male and female voiding dysfunction, neurogenic bladder, and complex lower urinary tract and pelvic floor reconstruction. He has authored or co-authored numerous books, book chapters and journal articles, and is recognized internationally as a leader in his field. He is deeply interested in and regularly speaks about healthcare and physician burnout. His lofty goal is to provide a world that lifts up physicians and other healthcare providers who serve. He is hopeful that writing "*Fist Pumps...The Prescription for Physician Burnout*," will bring him one step closer to reaching his objective.



Guy Manetti, MD

Dr. Manetti graduated from the University of Pennsylvania and earned his Medical Degree from the University of Medicine

& Dentistry of New Jersey. He completed his general surgery internship and urology residency at Yale New Haven Hospital in New Haven, Connecticut, where he served as chief resident of Urology. Dr. Manetti has published numerous peer-reviewed articles and was awarded a research grant from the Department of Surgery at Yale University. In addition to general urology, Dr. Manetti's areas of special expertise and interest are minimally invasive surgery of the kidney, robotic prostate surgery, management of stone disease and erectile dysfunction. He is a member of American Urological Association and an attending at Danbury Hospital/Western Connecticut Health Network.



Joy Maulik, CRNP

Joy Maulik began his career in healthcare in 2007 and graduated with his Nurse Practitioner degree from Wilmington University in 2015. There he was selected as class Valedictorian in addition, to being awarded a certificate in Academic Excellence. During his career he has assumed various roles in both clinical and leadership positions. His experience ranges from clinical nurse supervisor, community based primary care, and Director of Critical Care for a level III trauma center. He is currently practicing at Chesapeake Urology specializing in general Urology with sub specialization in Prostate Cancer and Men's health. He also serves as member of lead APP team with United Urology, as well as Co-Chair of APP council at Tidal Health Care. He lives on the Eastern Shore of Maryland, with his wife of sixteen years and his eleven year old twins. He believes in learning from defects and investing in processes which cultivates optimal outcome and relationship building.



John McManus

Mr. McManus is the President and founder of The McManus Group LLC, a consulting firm specializing in strategic policy, political counsel and advocacy for health care clients with issues before Congress and the Administration. The McManus Group services clients who are leaders in their respective field across the health care spectrum from the pharmaceutical, biotechnology and medical device industries, to physician groups and employee benefit managers. The McManus Group was founded in 2004 and has built a reputation of substantive policy expertise that is trusted by key policy makers in both legislative chambers and in the Administration.

Before founding The McManus Group, Mr. McManus served Chairman Bill Thomas as the Staff Director of the Ways and Means Health Subcommittee, where he led the policy development, negotiations and drafting of the Medicare Prescription Drug, Improvement and Modernization Act of 2003. The MMA provided a market-based, comprehensive prescription drug benefit, reformed Medicare and established Health Savings Accounts. Mr. McManus worked for Chairman Thomas for six years where he also played an instrumental role in the Medicare Commission, Patients' Bill of Rights and other Medicare legislation.

Before working for Chairman Thomas on Capitol Hill, Mr. McManus worked for Eli Lilly & Company as a Senior Associate from 1994-97 and for the Maryland House of Delegates from 1993-94 as a Research Analyst, briefing the Chairman of the Economic Matters Committee and the members of the Health Subcommittee.

Mr. McManus earned his Masters of Public Policy from Duke University and Bachelor of Arts from Washington and Lee University. Mr. McManus serves on the Board of Advisors of the Williams School of Commerce, Economics and Politics of Washington and Lee University.



Jennifer Miles-Thomas, MD

Dr. Miles-Thomas earned her medical degree from Northwestern University Feinberg School of Medicine in Chicago, Illinois in 2001 after completing her undergraduate degree in Biology at Virginia Commonwealth University. She served her general surgery internship in the Department of Surgery at The Johns Hopkins Hospital in Baltimore, Maryland, where she also completed her urology residency and fellowships in Female Urology and Endourology at The James Buchanan Brady Urological Institute. Dr. Miles-Thomas is a Diplomate of the American Board of Urology and is also board certified in Female Pelvic Medicine and Reconstructive Surgery. She is currently the President of Urology of Virginia and the Medical Director of the Pelvic Health program at Chesapeake Regional Healthcare. Dr. Miles-Thomas provides specialized care in female reconstructive surgery, pelvic prolapse, incontinence, complicated urinary disorders, and disorders of the urinary system due to neurologic disease. She is a member of the American Urological Association (AUA), Mid-Atlantic Section of the AUA, Large Urology Group Practice Association (LUGPA), Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction, American Urogynecologic Society, and Society of Women in Urology.

Dr. Miles-Thomas has published several textbook chapters regarding voiding dysfunction. She has presented her research at numerous national and international medical conferences. She is also currently the Principal Investigator for many Overactive Bladder Trials at Urology of Virginia.



Chris Mitchell, MD

Dr. Mitchell is Christiana Care's Director of Robotic Surgery at the Helen F. Graham Cancer & Research Institute. Dr. Mitchell is

a physician partner at Brandywine Urology Consultants. Dr. Mitchell brings expertise in some of the most advanced and complex minimally invasive robotic surgical techniques in the field of urology to Delaware.

Dr. Mitchell specializes in minimally invasive robotic surgery to treat benign and malignant diseases of the genitourinary tract; including partial nephrectomy for kidney tumors, nerve sparing prostatectomy for prostate cancer and complex ureteral reconstruction. Dr. Mitchell is pleased to bring Holmium Laser Enucleation of the Prostate (HOLEP) procedure to Christiana Care; making this area one of the few locations in the country to offer this new state-of-the-art urological procedure. This new procedure is shown to be highly effective in treating enlarged prostate or BPH (benign prostate hyperplasia), a non-cancerous that affects most men as they age.

Dr. Mitchell graduated from Villanova University in 2004 with a Bachelor of Science degree in Biology. He earned his Medical Degree from the University of Maryland in 2008 where he was the proud recipient of the Gold Medal Award presented to only one graduate with outstanding scholarly accomplishments. He completed a one-year General Surgery internship and his residency training in urology at the Mayo Clinic in Rochester, Minnesota. Dr. Mitchell then completed an extensive two-year fellowship in laparoscopy/endourology at Vanderbilt Medical Center in Nashville, Tennessee.



David S. Morris, MD

Originally from Cleveland in East Tennessee, Dr. Morris attended The Baylor School in Chattanooga, TN. He graduated Summa Cum Laude from Vanderbilt University and then earned his doctorate from Vanderbilt University School of Medicine. Dr. Morris completed his residency training at The University of Michigan in Ann Arbor, MI with a special research interest in genetics that predict the aggressiveness of prostate and bladder cancers. Since completion of training, he has been with Urology Associates in Nashville, Tennessee. He serves the group as President and the Co-director for the Advanced Therapeutics Center. The ATC center also works closely


with the Clinical Research Department as a center for multiple phase 2 and 3 trials primarily focused on GU oncology.



Neal Patel, MD

Chief Technology Officer and Director of Robotic Surgery at Advanced Urology Institute of Georgia, PC in Snellville, GA. Dr. Neal Patel, a Georgia native, earned his medical degree from Chicago Medical School as part of an engineering in medicine program with the Illinois Institute of Technology where he graduated Cum Laude with a degree in Molecular Biochemistry and Biophysics. After completing residency in Urologic Surgery at Rutgers Robert Wood Johnson Medical School in New Jersey, he joined the USC Institute of Urology as a Felix and Mildred Yip Fellow in Advanced Robotics and Laparoscopy.

Dr. Patel has been active with the American Medical Association, the Illinois State Medical Society and the Chicago Medical Society. He has served on the Board of Trustees of the Chicago Medical Society, and has held multiple leadership positions within organized medicine at both local and national levels. In 2009, Dr. Patel was invited to attend the TEDMED inaugural conference in San Diego and has since been an invited alumnus.



Sarah Nayeboadri, PA-C

Sarah Nayeboadri is a Physician Assistant with Advanced Urology in the Atlanta area. She pursued a Bachelor's degree in Biomedical Engineering at Georgia Institute of Technology where she graduated summa cum laude. She attended Mercer University pursuing a Master of Medical Science in Physician Assistant Studies. She received the Scholastic Achievement Award for having the highest GPA of her physician assistant class. Sarah has worked at Advanced Urology for five years. She has particular

interest in overactive bladder, benign prostatic hyperplasia, interstitial cystitis, as well as numerous other general urology ailments. She also assists in a variety of open and robotic surgical cases with many of the physicians in her practice. She performs clinic procedures and assists with outpatient ambulatory surgery center procedures as well.



Elizabeth Persels, RN

Elizabeth Persels serves as Clinical Research Manager of Wichita Urology Group, a research and comprehensive urology practice in Wichita, KS. Elizabeth has over 10 years of experience throughout 200+ multispecialty trials in clinical research. Prior to joining Wichita Urology, Elizabeth served as the lead clinical research nurse and manager for cardiovascular research and multiple roles within oncology research.

During her time at Wichita Urology, Elizabeth has increased patient accrual, financial margins, promoted staff retention efforts, and has streamlined and created processes that have provided the exponential growth to the research department.

Elizabeth's professional passions include facilitating growth within the research community by assisting new program start-ups, contract and budget negotiations, and continual education to expand her knowledge and understanding of the research industry.



Twila Puritty

Twila Puritty is the CEO of Wichita Urology and has been with the practice for 11 years. Wichita Urology is a group of 20 providers with 3 locations in Wichita and 11 outreach locations in rural Kansas communities. Prior to joining Wichita urology, Twila had a 25+ year career leading radiology groups and imaging centers in Florida, California, Oklahoma, Nebraska and Kansas.

In her eleven years with Wichita Urology, the practice has grown by building a free-standing radiation oncology facility, adding a successful clinical trial program, establishing an advanced prostate cancer clinic, developing catheter dispensing, and in-office dispensing programs. The group recently opened a new 26,000 sq. ft. facility. The building houses a 14,000 sq. ft. ambulatory surgery center that opened the summer of 2021. Mrs. Puritty and the Wichita Urology physicians have also developed multiple LLCs for equipment and building leasing.

Twila's professional passions are facilitating growth initiatives, increasing clinical productivity, and enhancing collection efforts through microanalysis with the result of maximizing shareholder wealth.

Twila and her husband Ross have five children.



Phil Roe, MD

Phil grew up in Clarksville Tennessee and graduated from Austin Peay in 1967 with a degree in Biology and Chemistry and the University of Tennessee College of Medicine in 1970. Following graduation he served in Korea at Camp Casey with the Second Infantry Division. After military service he returned to Memphis to complete his residency in OB/GYN. After residency he moved to Johnson City Tennessee where he practiced for 31 years delivering nearly 5,000 fellow Tennesseans. He served on the clinical faculty of Quillen College of Medicine for 25 years. In 2008 he retired and ran for Congress representing the First Congressional District of Tennessee. While in Congress he served on the Education and Workforce Committee and the Veterans Affairs Committee. He was Chairman and Ranking member of the VA Committee. While in Congress he Co-Chaired the Doctors Caucus, Adult Literacy Caucus and Health Caucus. He also served on the GOP Whip Team. He was able to pass numerous pieces of legislation related to healthcare and Veterans including the transformative VA Mission act. He retired after 6 terms on 2021. After retirement he has continued to serve on the following organizations. USIEA (US Israel Education Association), Dole Foundation Board, Trustee at Austin

Peay University, National Prayer Breakfast Board. He is enjoying retirement with his wife Clarinda, grandchildren and his toy Australian Shepards Gus and Sassie.



Cass Schaedig – Principal, Willow Run Analytics, LLC

With over 35 years in the healthcare industry, Cass has perfected the ability to mine, synthesize and distill healthcare data to reveal and analyze the core functions of medical practices. After 10 years of working for data analytics firms, Cass started Trellis Healthcare and developed its flagship product, InfoDive®, a powerful business intelligence tool used by medical practices to make data-backed decisions to improve practice performance. InfoDive® has been used by over 600 practices and health systems representing both primary care, specialists, and ancillary providers. The company was acquired in 2013 and Cass continue to lead the product for the next 10 years, including the support of value-based care payer programs.

Cass offers her extensive background in data analytics through consulting services to support improvements to practice efficiency, provider productivity, revenue cycle management and payer reimbursement. Services also support advocacy initiatives with government and commercial payers.



Daniel Schonwald, CMPE

Practice Administrator, Comprehensive Urologic Care, SC in Lake Barrington, IL

As the Practice Administrator of Comprehensive Urologic Care, SC Mr.

Schonwald believes in using technology and analytics to level the playing field between small practices and the large commercial payers, and continually improving processes to provide a rewarding environment for physicians and staff to deliver the best medical care to their patients.

Born and raised in Oklahoma City, OK, Mr. Schonwald earned his Bachelor of Arts degree from Brandeis University in Waltham, Massachusetts. He has been a private practice executive for 23 years serving clinics in Oklahoma City and in Chicago, IL where he currently resides. He has obtained his Certified Medical Practice Executive certificate from MGMA.



Geoffrey Sklar, MD, FACS

Dr. Sklar received his undergraduate training at the University of Maryland. He subsequently attended the University of Maryland School of Medicine and completed his urology residency at the University of Maryland Medical Center in 1994 and became a Diplomate of the American Board of Urology in 1996. He then became faculty at the University of Maryland School of Medicine and ultimately appointed Chief of the Division of Urology and Residency Director at the University of Maryland School of Medicine. He subsequently joined Chesapeake Urology in 2006 and was appointed Chief Medical Officer in 2009. Additionally, he was Chief of Urology and Director of Urologic Oncology, Associate Chief of Surgery, Chief of Credentials Committee and President of the Medical Staff of the University of Maryland Baltimore Washington Medical Center.

In July of 2017 Dr. Sklar became the Associate Director of the Weinberg Cancer Institute and Chief of the Division of Urologic Oncology at Medstar Franklin Square Medical Center. In 2018 Dr. Sklar was appointed Chief Medical officer of United Urology Group. He oversees risk management, quality assurance, compliance in his current role.

Dr. Sklar has more than 40 published manuscripts and has delivered over 500 lectures worldwide. He has participated more than 30 clinical trials. He was named an innovator in urology in 1997. Currently Dr. Sklar is a reviewer for the Journal of Urology, Urology Practice, Urology, the World Journal of Urology, the Journal of Sexual Medicine and the American Journal of Transplantation.

Dr. Sklar's clinical interests include: GU Oncology, Neobladders, Sexual function (ED, Peyronie's Disease), and genitourinary reconstruction. In addition to his interests in Urology, Dr. Sklar was a coach of an international martial arts team and coached many world champion martial artists.



Tracy Spicer

Avenue Solutions' founding partner Tracy Spicer is a 20-year veteran of political campaigns at every level. Ms. Spicer began her involvement in politics in 1992 in former U.S. Senator Edward M. Kennedy's Senate office before transitioning to his campaign staff in 1994 to assist in his successful re-election campaign against Mitt Romney. Since that time, she has worked with and coordinated numerous campaigns, ranging from municipal and state candidates to the U.S. Congress as well as the White House. Tracy served as a longtime aide to former Senator Kennedy, quickly rising to Political Director and Deputy Chief of Staff. During her decade of experience on Capitol Hill, she coordinated successful political and legislative strategies for Senator Kennedy. Tracy managed Senator Kennedy's legislative priorities in the areas of healthcare, education, labor and economic development and strategically worked with Democratic Senators and their political campaign committees to position legislative priorities for political success.

Tracy is widely recognized for her political acumen and expertise in designing legislative and regulatory strategies and her established network of long-standing professional contacts among elected

officials, appointed policymakers and their staffs. She draws on her vast political and legislative experience to help clients in navigate the labyrinth of Capitol Hill and government bureaucracy and to position them strategically to head off obstacles, find common ground and achieve success.

As a founding partner of Avenue Solutions, Tracy advises a broad array of clients, including Fortune 100 companies, non-profit organizations, associations and coalitions. She is particularly noted for her expertise in healthcare policy. On behalf of her clients, Tracy has played a leading role in the consideration, negotiation and implementation of the Affordable Care Act (healthcare reform); Medicare and Medicaid legislation; passage and implementation of MACRA and healthcare delivery system reform; and the value and innovation of prescription drugs.

Tracy is a graduate of Hobart and William Smith Colleges in Geneva, NY where she earned her bachelor's degree in Political Science.



Jeffrey Spier, MD, Chair, LUGPA Program Committee

Dr. Spier is President of Rio Grande Urology (RGU) founded in 2008 serving West Texas and Southern New Mexico. RGU has 23 providers with 5 offices and 2 radiation centers employing over 250 staff in El Paso, Texas and Las Cruces, New Mexico. Dr. Spier has overseen the tremendous growth of RGU, becoming the largest private practice physician group in the region. Rio Grande Urology continues to expand with the formation of the Rio Grande Cancer Specialists (RGCS) providing radiation therapy as well as the RGCS Advanced Prostate Cancer. This center of excellence includes clinical research with ongoing expansion into other genitourinary oncologic conditions. "RGU is committed to serving the urologic and oncologic needs of their patients, providing state of the art and compassionate care," said Dr. Spier.

Dr. Spier is board certified by the American Board of Urology and member of the American Urological Association and South Central Section of the AUA. He graduated from the University of Texas Medical Branch in Galveston, Texas where he also completed his Urology residency training. He currently serves on the Large Urology Group Practice Association (LUGPA) Board of Directors and serves as secretary. He is currently President of the El Paso County Medical Society, board member of the University of Texas at Galveston Alumni Board of Trustees and has served on the board of the Texas Urological Society.



Michael Szostak, MD

Dr. Szostak is a Board Certified urologist originally from Upstate NY with over 20 years of clinical and surgical experience in a large single specialty urology group. He was one of the founding members of Urology Specialists of West Florida which is now the Pinellas Care Center of Advanced Urology Institute. Over the years he has participated in many leadership and administrative roles within the urology group including being an executive committee member, chair of the quality committee and managing partner. He has also participated in BayCare Hospitals leadership programs, was chair of surgery and urology, medical staff president, and served in multiple advisory and clinical quality roles.

Dr Szostak is passionate about organizational development, collaborating with teams, supporting relationships, and enjoys a challenge. In 2021 he transitioned out of full-time clinical practice and worked as the Assistant Chief Medical Officer for a 600 bed hospital before re-joining AUI as the Chief Medical Officer in August 2022.

In his spare time, he and his family enjoy domestic and international travel and medical missions. More recently he completed an MBA with a medical management concentration.

He feels fortunate to serve such a large and diverse group with AUI and Solaris who work hard every day to provide the highest quality care to our communities.



John Tillett, MD, FACS

Former U.S. Navy Medical Corps Lieutenant Commander John Tillett, MD FACS, practiced urology in the military and also private practice in Florida before joining TUCC in 2016. He is currently an assistant professor at the University of Colorado School of Medicine. He is also is the director of the Urology training program for the Swedish Medical Center General Surgery residency program. He is also actively involved as a sub-investigator in multiple clinical trials in the TUCC Research Department.

Dr. Tillett graduated magna cum laude from Vanderbilt University and received his medical doctorate from Emory University School of Medicine, where he earned the Joseph B. Whitehead Surgery Scholarship. He completed his residency and served as Chief Resident at Emory, where he was recognized with the Department of Urology Award for Outstanding Academic Achievement and the prestigious Resident Achievement Award by the Society of Laparoendoscopic Surgeons. In 2010, Dr. Tillett was recognized by the Deputy Surgeon General of the U.S.Navy as being among the top five urology providers in the Navy ranked for satisfaction by outpatient clinic patients. He is certified by the American Board of Urology and is a fellow of the American College of Surgeons.



Anup Vora, MD

Dr. Vora practices general urology at Chesapeake Urology and sees adult patients and teens ages 15 and over. He focuses on urologic cancers, bladder control conditions including incontinence and overactive bladder, enlarged prostate (BPH), kidney stones, elevated PSA counseling, hematuria, erectile dysfunction, low testosterone, vasectomy, and urinary tract infections. He also performs the UroLift procedure for the treatment of BPH/enlarged prostate.

Dr. Vora completed a fellowship in urologic oncology at the preeminent Cleveland Clinic Florida, and he specializes in the treatment of bladder cancer (non-invasive and advanced), kidney cancer (small and advanced tumors), and prostate cancer (including primary and salvage surgery for complex cases).



Kirk J. Wojno, MD

Dr. Wojno is a pathologist at Comprehensive Urology in Royal Oak, Michigan. He is using digital pathology and artificial intelligence to transform the field of anatomic and molecular pathology. He also serves as CMO of Immunis.AI where he works closely with clinicians and laboratory scientists to develop and transform modern molecular laboratory next generation sequencing patient data into relevant and clinically useful information that impacts patients' lives. As director of clinical research for Michigan Healthcare professionals he oversees numerous large scale multi-institutional clinical trials.

ORGOVYX[®]
(relugolix) 120 mg
tablets

**DIVE INTO
WHAT ORGOVYX
OFFERS.**

**LEARN MORE AT
ORGOVYXHCP.COM**



ORGOVYX[®] and its associated logo are registered trademarks of Myovant Sciences GmbH.
©2022 Myovant Sciences GmbH and Pfizer Inc. All rights reserved.
PP-US-REL-2200227 07/22

AbbVie



AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.

Accord BioPharma



Accord BioPharma is finding ways to reimagine therapies and help those who depend on their continued evolution with a pipeline of specialty products designed for patient needs.

This attention to our patients, their abilities, and care goals is our approach, and our difference. It's how we continue to challenge the status quo for patient and provider expectations in oncology, immunology, and critical care. The medicine may be where it starts, but in order to enhance the patients' experience, we must deliver therapies that go beyond just the medicine, beyond biology.

Astellas Pharma and Pfizer Oncology



Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at <https://www.astellas.com/en>.

AstraZeneca



AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. For more information, please visit www.astrazeneca-us.com.

Bayer HealthCare



Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing aging population. Bayer is committed to the principles of sustaining development, and the Bayer brand stands for trust, reliability, and quality throughout the world.

ImmunityBio



At **ImmunityBio**, we envision a day when we no longer fear cancer, but are able to **conquer** it. Our scientists are working to develop remarkable new therapies that amplify both the innate and adaptive branches of the immune system. The goal: to reprogram the **patient's immune system** and treat the host rather than just the disease.

Janssen Biotech, Inc.



At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference; Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.

Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Biotech, Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Lantheus



With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.

Merck



At Merck, our goal is to translate breakthrough science into innovative oncology medicines. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry.

Myriad Genetics, Inc.



Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Novartis



Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at <https://www.novartis.com> and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

Pfizer Oncology



Pfizer Oncology is committed to advancing medicines wherever we believe we can make a difference for people living with cancer. We have an industry-leading portfolio of 24 approved cancer medicines and biosimilars across 30+ indications—and are focused on delivering breakthroughs in breast cancer, genitourinary cancer, hematology, and precision medicine.

Sumitomo Pharma America, Inc.



Sumitomo Pharma America (SMPA) is focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapies. The company's diverse portfolio includes several marketed products and a robust pipeline of early- to late-stage assets. SMPA leverages proprietary in-house advanced analytics and computational technology platforms to accelerate discovery, research, and help bring novel therapies to patients sooner. SMPA is a Sumitomo Pharma Co., Ltd., company. For more information on SMPA, visit our website <https://www.us.sumitomo-pharma.com> or follow us on LinkedIn.

Sun Pharmaceutical Industries Inc., USA



Sun Pharma is the 4th largest specialty generic pharmaceutical company in the world, providing high-quality, affordable medicines in over 150 countries. Our mission is to enhance people's lives with innovative and quality generic, branded, and over-the-counter medicines, providing exceptional value in our communities. In the US, Sun Pharma is focused on helping patients in Generics, Dermatology, Oncology, and Ophthalmology.

Telix Pharmaceuticals



Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic ('theranostic') products using targeted radiation. Our products use targeted radiation to image disease and deliver truly personalized therapy in areas of significant unmet medical need. Telix's theranostics pipeline aims to address significant unmet medical need in prostate, kidney, brain, and blood cancers, and a range of rare diseases.

Tolmar Inc.



Committed to scientific advancement. Passionate about patient care.

At Tolmar, science drives everything we do. Through a relentless focus on technology, science, partnership and excellence, we seek to advance patient care and deliver value through innovative therapies and services.

The Tolmar portfolio includes specialty products for urology, oncology, men's health, and rare disease. The invention, development and worldwide approval of ELIGARD® (leuprolide acetate for injectable suspension) delivers innovation and commitment to the urology, oncology and hospital communities, providers and patients. With the acquisition of JATENZO® (testosterone undecanoate) capsules, CIII, Tolmar continues to show its dedication to men's health.

Our fully integrated model ensures that Tolmar controls all aspects of the research, development, approval and commercialization of our products. With numerous FDA-approved products, we have earned a global reputation for our strict standards, expertise in manufacturing and proven record in regulatory and clinical development. Our robust pipeline harnesses our expertise and experience, and ensures that we will carry this legacy well into the future.

UroGen Pharma, Inc.



UroGen is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated because patients deserve better options. Our vision to pioneer new treatments is grounded in our innovative drug delivery technology platform RTGel™, our promising pipeline, and a collaborative drive for bold results.

MY PERSPECTIVE AS A PATIENT AND AN ADVOCATE FOR PATIENTS

Saturday, November 4th | 9:00 a.m. - 9:45 a.m.
Grand Harbor Ballroom North



Will Flanary, MD
AKA
Dr. Glaucomflecken

@dglaucomflecken
 @drglaucomflecken
 @docglauc


THANK YOU TO
OUR SPONSOR



Personalized medicine just got more personal


Prolaris® is...

The ONLY biomarker developed on untreated men with a consistently proven threshold to best guide active surveillance decisions¹⁻³




Prolaris identifies **2x** as many men in the low-risk group for active surveillance than our brand competitors⁴

The ONLY biomarker to provide two validated thresholds^{3,5-6}



The ONLY biomarker to quantify personalized benefits of adding ADT to radiation therapy⁷



The ONLY biomarker to consistently meet its designated endpoints in validation studies^{1,2,5,6,8-10}



References:

- Cuzick J, et al. Br J Cancer 2012; 106:1095-1099
- Cuzick J, et al. Br J Cancer 2015 Jul; 113(3):382-9
- Lin D, et al. Urol Oncol. 2018 Jun;36(6): 310.e7-310.e13
- Hu, J. C., et al. JCO Precision Oncology, 2018; 1-15
- Tward J, et al. Clin Genitourin Cancer. 2021 Aug;19(4):296-304.e3
- Tward J, et al. Int J Radiat Oncol Biol Phys. 2021 Oct 3
- Tward JD, et al. JCO 41, no. 16_suppl (June 01, 2023):5030
- Beksac AT, et al. Cancer Rep (Hoboken). 2021 Dec 20
- Lin, et al. JCO 2020 Mar 4
- Chappidi M, et al. Poster session presented at: WsAUA; October 2022; Kauai, HI

2024 Regional Meetings



LUGPA
Integrated Practices
Comprehensive Care

February 10-11, 2024
Grand Hyatt Vail
Vail, Colorado



(Taking place immediately prior to the IPCU meeting at the same location.)

April 12-13, 2024
Nashville Renaissance,
Nashville, TN



June 7-8, 2024
The Wynn,
Las Vegas, NV



Urology Resident Summit and Job Fair

March 1-2, 2024
Grand Hyatt DFW
Dallas, TX

LUGPA's yearly Resident Summit is an essential professional education and networking opportunity for urology residents and practices from across the USA looking to hire new physicians.



LUGPA
Integrated Practices
Comprehensive Care

NEW!

ASC Academy

March 14-16, 2024
Disney World Swan Hotel,
Lake Buena Vista, FL

LUGPA's new Ambulatory Surgery Center Academy will highlight important clinical and administrative elements to developing a safe, efficient ASC. Staffing, regulatory compliance and various procedures will be discussed. Whether your practice already has an ASC or not, this program has something for you.

April 4-6, 2024
Westin Irving Convention Ctr.
Dallas, Texas

Prostate Cancer Academy

Bladder & Kidney Cancer Academy

October 24-26, 2024
Marriott Downtown,
Philadelphia, PA



LUGPA
Integrated Practices
Comprehensive Care

co-hosting with



Specialty Networks

LUGPA 2024 Annual Meeting

LUGPA's Annual Meeting is the premiere education and networking event for independent urology practice physicians, administrators, and other key staff.



LUGPA
Integrated Practices
Comprehensive Care

November 14-16, 2024
Marriott Magnificent Mile Hotel,
Chicago, IL

Visit www.LUGPA.org/Events



We're *in* urology.

We're listening. We're learning.

We're investing in urology-specific resources.

We're advancing clinical innovations,
so you can help patients.

We're reimagining care so your patients
with cancer can redefine living.

This is why we're all in.
For you—and for them.

We're **Janssen**,
and we're *in* urology.

rater8

Outshine Your Competition with a Perfect Online Reputation

Effortlessly build 5-star patient reviews with our top-rated healthcare reputation management solution.

Rated #1 on Capterra and G2!



"rater8 has exceeded expectations. We immediately started to receive valuable feedback from our patients, and we've seen our Google reviews go from 2.7 stars to 4.8 stars. I would not hesitate to refer rater8 to any of my business colleagues."

– Whitt Holder, CEO, Amarillo Urology Associates, LLP



Amarillo Urology Associates, LLP



HIXSON UROLOGY

Visit us at booth #104 and enter to win our \$300 cash giveaway!

🌐 rater8.com | ✉ info@rater8.com

Thank You for Attending the
LUGPA 2023 Annual Meeting
and for Your Continued
Support and Membership

SAVE THE DATE
LUGPA
2024 Annual Meeting

November 14 – 16, 2024
Chicago Downtown Marriott
Magnificent Mile Hotel | Chicago, IL



We are...



Thrive in Independent Practice

With the Group that's Transforming
Urology Care in America

As a pioneering force in the industry, Solaris Health has the size and scale to protect independent providers who face the headwinds of a widely consolidating healthcare landscape. Solaris is a consortium of leading urology groups that that balances platform support with local autonomy for physicians who are committed to leading edge, innovative care.

At Solaris we are **BETTER TOGETHER.**

SolarisHP.com